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Recent malaria epidemics in KwaZulu-Natal indicate that effective anti-malarial therapy
is essential for malaria control. Although artemether-lumefantrine has been used as first-
line treatment for uncomplicated Plasmodium falciparum malaria in northern KwaZulu-
Natal since 2001, its efficacy has not been assessed since 2002. The objectives of this
study were to quantify the proportion of patients treated for uncomplicated P. falciparum
malaria with artemether-lumefantrine who failed treatment after 28 days, and to
determine the prevalence of molecular markers associated with artemether-lumefantrine
and chloroquine resistance.
Methods
An observational cohort of 49 symptomatic patients, diagnosed with uncomplicated
P. falciparum malaria by rapid diagnostic test, had blood taken for malaria blood films
and P. falciparum DNA polymerase chain reaction (PCR). Following diagnosis, patients
were treated with artemether-lumefantrine (Coartem®) and invited to return to the health
facility after 28 days for repeat blood film and PCR. All PCR P. falciparum positive
samples were analysed for molecular markers of lumefantrine and chloroquine resistance.
Results
Of 49 patients recruited on the basis of a positive rapid diagnostic test, only 16 were
confirmed to have P. falciparum by PCR. At follow-up, 14 were PCR-negative for
malaria, one was lost to follow-up and one blood specimen had insufficient blood for a
PCR analysis. All 16 with PCR-confirmed malaria carried a single copy of the multi-drug
resistant (mdr1) gene, and the wild type asparagine allele mdr1 codon 86 (mdr1 86N).
Ten of the 16 samples carried the wild type haplotype (CVMNK) at codons 72-76 of the
chloroquine resistance transporter gene (pfcrt); three samples carried the resistant CVIET




The absence of mdr1 gene copy number variation detected in this study suggests
lumefantrine resistance has yet to emerge in KwaZulu-Natal. In addition, data from this
investigation implies the possible re-emergence of chloroquine-sensitive parasites.
Results from this study must be viewed with caution, given the extremely small sample
size.
Recommendations
A larger study is needed to accurately determine therapeutic efficacy of artemether-
lumefantrine and resistance marker prevalence. The high proportion of rapid diagnostic
test false-positive results requires further investigation.
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Artemether-lumefantrine (AL) has been used as the first line treatment of
uncomplicated Plasmodium falciparum malaria in northern KwaZulu-Natal since 2001
[1, 2] and is recommended for this purpose by the South African Department of Health
[3]. The recent history of malaria epidemics in KwaZulu-Natal indicates that the
therapeutic effectiveness of the anti-malarial medication used to treat patients suffering
malaria is vital for malaria control and must be regularly assessed. Failure to do so risks
the undetected emergence of antimalarial drug resistance, contributing to a malaria
epidemic, which has major public health and economic consequences for the area,
province and even country. A study of the effectiveness of AL should either confirm the
continuing efficacy of the medicine, or provide a warning as to the acquisition of
resistance by malaria parasites and the need to seek an alternative therapy before an
epidemic occurs.
Recent history of P. falciparum antimalarial drug resistance in
KwaZulu-Natal
South Africa, along with neighbouring Namibia, Botswana, Zimbabwe and Swaziland,
is classified by the World Health Organisation (WHO) as a low malaria transmission
country [4]. Most of South Africa’s population is not at risk from malaria, however
malaria remains endemic mainly along the north-eastern border with Mozambique and
Swaziland [4]. Mozambique is classified as a high malaria transmission country, with
most of the population at high risk of malaria [4]. The Province of KwaZulu-Natal
borders on both Mozambique and Swaziland, and malaria risk areas may be seen in
figure 1 [5].
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Figure 1: Malaria Risk Map of KwaZulu-Natal
Chloroquine resistance was first detected in South Africa in 1985 [6]. In 1988, due to
the emergence and spread of chloroquine-resistant P. falciparum malaria, sulfadoxine-
pyrimethamine (SP) replaced chloroquine as the first-line treatment for uncomplicated
P. falciparum malaria in KwaZulu-Natal [1, 7, 8]. This drug remained effective until
1996 when malaria incidence increased dramatically. Between 1996 and 2000, northern
KwaZulu-Natal suffered increasingly severe malaria epidemics with more than 40 000
malaria notifications in 2000 [9]. Only in 2000 did a clinical study show that P.
falciparum parasites in the region had developed resistance to sulfadoxine-
pyrimethamine, the then recommended first line treatment for malaria, rendering it
largely ineffective in northern KwaZulu-Natal [7]. Subsequently the change of first-line
medication to artemether-lumefantrine (AL), together with change of insecticide used
for residual house spraying to DDT, dramatically reduced malaria incidence in northern
KwaZulu-Natal [1, 2]. It has been estimated that the delay in changing first-line
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treatment for malaria between 1996 and 2000 was responsible for substantial morbidity
and mortality, as well as contributing to the size of the epidemic [10]. Artemisinin based
combination therapy (ACT) is recommended for the treatment of uncomplicated P.
falciparum malaria by the World Health Organization, and artemether-lumefantrine  is
one recommended combination [4, 8]. Artemether-lumefantrine is recommended for the
treatment of uncomplicated P. falciparum by the South African Department of Health
[3]. Studies of the therapeutic efficacy of artemether-lumefantrine in 2001 and 2002
indicated that AL was effective for treating uncomplicated malaria in northern
KwaZulu-Natal [1, 11, 12].
Statement of problem
Since 2002 there have been no further studies in KwaZulu-Natal, or South Africa, of the
continuing therapeutic effectiveness of AL in the treatment of uncomplicated malaria.
What needs to be known?
The WHO recommends routinely monitoring antimalarial resistance at least every three
years, and a change in antimalarial medicine if the treatment failure proportion ≥ 10%
after follow-up for at least 28 days [4, 8].
Purpose of research
For these reasons it was considered that an assessment of the efficacy of AL in
KwaZulu-Natal was overdue and required in the interests of public health.
Specific objectives
The specific objectives of the study are: to quantify the proportion of patients treated
with artemether-lumefantrine, who fail to clear P. falciparum from their blood 28 days
after treatment; test for molecular markers of malarial drug resistance to AL and
chloroquine; publish the results, and use the results to inform policy as to the best
choice of drug for the treatment for uncomplicated malaria in Umkhanyakude Health
District.
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CHAPTER II: LITERATURE REVIEW
Purpose of literature review
The purpose of this literature review is to provide an understanding of the present
situation with regards to malaria drug resistance in KwaZulu-Natal and the need for
drug efficacy testing. For this the author felt that the history of antimalarial medication
and malaria control should be included, as well as an outline of the biology of malaria
which is necessary to understand some of the challenges faced in controlling the
disease. Any discussion which involves malaria control must include reference to vector
control as well as antimalarial medication.
Introduction
According to the WHO World Malaria Report, in 2010 there were 216 million episodes
of malaria and 655 000 deaths from malaria worldwide [4]. Of these, 81% of the
malaria cases and 91% of the deaths were in Africa [4]. The Institute for Health Metrics
and Evaluation estimates a higher global mortality of 1,2 million of which 1,1 million
were in Africa [13]. Resistance of Plasmodium falciparum malaria, the most virulent
form of the disease, to antimalarial drugs has been one of the main obstacles to malaria
control in the world and South Africa [6, 14].
Biology of malaria
Malaria is caused by a single-cell protozoan parasite called Plasmodium [15]. There are
now five kinds of malaria described that infect humans: Plasmodium falciparum,
Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and Plasmodium
knowlesi, which was recently described in Borneo in 2009 [16, 17].
Most deaths are caused by Plasmodium falciparum, the other types rarely causing a fatal
illness [15].
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Malaria has a complicated life-cycle involving humans and the female Anopheles
mosquito [18]. Malaria is transmitted to humans through the bite of an infected female
Anopheles mosquito. The malaria parasites are first transported to the liver, where they
multiply, and then to the blood stream where they multiply further and destroy blood
cells. If an infected human is then bitten by an uninfected mosquito, the ingested
parasites then develop in the mosquito, taking 10-18 days to mature and appear in the
mosquito’s salivary glands, and are then able to infect a new human subject bitten by
the mosquito [18]. The lifespan of a mosquito is similar to the time taken for malaria
parasites to mature in the mosquito. In colder weather the lifespan is shortened
preventing maturation of the malaria parasites, hence malaria transmission occurs
mainly in warm climates [19].
Brief history of malaria – World
Symptoms of malaria have been described for thousands of years [18]. There have been
a number of important events contributing to the understanding of the biology of
malaria. In 1880 Laveran discovered the malaria parasite. In 1886 Golgi discovered
different forms of the disease, with different periodicity of fevers; in 1890 Grassi and
Filetti named Plasmodium vivax and Plasmodium malariae parasites; in 1897 Welch
named the Plasmodium falciparum parasite; and in 1897 Ross demonstrated that
malaria is transmitted by mosquitoes [18].
Important steps in the treatment and prevention of malaria
Treatment
There have been a number of significant historical steps in the treatment and prevention
of malaria. In China in 340 AD, the Qinghao plant or Artemesia annua was recognized
as a treatment for fever [18]. In 1971 the antimalarial drug artemesinin was isolated by
Chinese scientists, and today derivatives of artemesinin are used in many antimalarial
medications throughout the world, often in combination with other drugs [18].
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In Peru in 17th Century the bark of the Chinchona or quina tree was introduced to Jesuit
missionaries as a treatment for fevers by the indigenous people [18]. In 1820 quinine
was isolated from the bark by Pierre Pelletier and Joseph Caventou and became the
standard treatment for malaria, until the development of chloroquine in 1946, which
then became the preferred drug for treatment of malaria [18, 20, 21].
From 1946, chloroquine became increasingly used as a cheap effective antimalarial with
few side effects. By the 1960s it was widely available over the counter throughout
Africa [22].
Insecticide
Dichloro-diphenyl-trichloroethane (DDT) was first synthesised in 1874, however the
insecticidal properties of the compound were only discovered in 1939. DDT was first
used for malaria control during the Second World War by the Allies [18].
The Global Eradication Campaign was launched by the WHO in 1955 using insecticide
house spraying, antimalarial treatment and surveillance [18, 23]. It was successful in
eradicating malaria from the more temperate countries with seasonal malaria, but less
successful in most of the tropical endemic malarious countries. Often, an initial
reduction in malaria cases was followed by a rebound epidemic due to reduction of
population immunity to malaria [22].
History of antimalarial drug resistance - World
Malaria parasite resistance to antimalarial drugs, as well as mosquito insecticide
resistance, has been a major obstacle to malaria control worldwide, and remains so to
this day [4, 6, 23].
Pyrimethamine parasite resistance was noted in Kenya in the 1950s following regular
administration of the drug to villagers as part on an eradication programme, after which
use of the drug was stopped [23]. Between 1960 and 1962, the first reports of
chloroquine resistant malaria parasites came from South America and South East Asia
[23]. By 1973 chloroquine resistance had been reported more widely. The first
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chloroquine-resistant parasites from Africa were reported in Kenya and Tanzania in
1978 [21]. In subsequent years chloroquine resistance spread throughout Africa and the
world, such that by 1989 almost all malarious countries had chloroquine-resistant P.
falciparum [21, 23].
Sulfadoxine-pyrimethamine (SP) replaced chloroquine as first-line malaria treatment in
a number of countries – starting with Thailand in 1973, and including KwaZulu-Natal,
South Africa in 1988, Malawi in 1993, and Kenya and Botswana in 1997; however
resistance to SP quickly emerged [21].
Since 1999, artemesinin combination therapy has been recommended as a means of
reducing emergence of antimalarial resistance [24]. The mechanism of action of the
combination is through a rapid reduction in parasite numbers by artemesinin, and
clearance of the remaining parasites by a longer acting combination drug [24]. These
combinations are now recommended by the WHO [8]. Artemether-lumefantrine is the
recommended treatment for uncomplicated P. falciparum malaria by the South African
Department of Health [3].
Unfortunately resistance to artemisinin, characterised by slow clearing of the parasite
has now been reported from South-East Asia [25], and suggested in Kenya [26].
History of malaria control and antimalarial drug resistance in South
Africa
Vector control
In 1932, the first malaria control measures in South Africa were stimulated by the
adverse effect of the disease on sugar production [6]. The first malaria control measures
in South Africa were the use of Pyagra (liquid pyrethrum and kerosene) for indoor
spraying, which proved effective [6]. Pyagra was replaced by DDT in 1946 [6]. DDT
remained the insecticide used the house spraying in northern KwaZulu-Natal until 1996,
when DDT was replaced by the pyrethroid insecticide deltamethrin [27]. This change in
insecticide was followed by a dramatic increase in the area between 1996 and 2000 [1,
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2, 27]. In 2000 deltamethrin resistant, but DDT sensitive Anopheles funestus mosquitoes
were identified [27]. This discovery led to the reintroduction of DDT house-spraying in
northern KwaZulu-Natal [1], which was followed by a dramatic increase in the
incidence of malaria in the region [1].
Antimalarial drug resistance
Chloroquine resistance was first detected in KwaZulu-Natal in 1985 [6, 28]. This
resistance was shown to have increased by 1988 [29] which led to sulfadoxine-
pyrimethamine (SP) replacing chloroquine as the first line treatment for uncomplicated
P. falciparum malaria in KwaZulu-Natal [1, 6]. This drug remained effective until 1996
when malaria incidence sharply increased. Between 1996 and 2000 northern KwaZulu-
Natal suffered increasingly severe malaria epidemics with more than 40 000 malaria
cases notified in 2000 [1, 2, 9]. Analysis of health institution statistics in northern
KwaZulu-Natal indicated more than 60,000 malaria cases treated [1]. Only in 2000 did
a clinical study show that P. falciparum parasites in the region had developed resistance
to sulfadoxine-pyrimethamine, the then recommended first line treatment for malaria,
rendering it largely ineffective in northern KwaZulu-Natal [7]. Subsequently the change
of first-line medication to artemether-lumefantrine, together with change of insecticide
used for residual house spraying to DDT, dramatically reduced malaria incidence in
northern KwaZulu-Natal [1, 2]. It has been estimated that the delay in changing first-
line treatment for malaria between 1996 and 2000 was responsible for substantial
morbidity and mortality, as well as contributing to the size of the epidemic [10].
Artemesinin based combination therapy is recommended for the treatment of
uncomplicated P. falciparum malaria by the World Health Organization [4], and
artemether-lumefantrine (AL) is one of the recommended combinations [8]. Studies of
the therapeutic efficacy of artemether-lumefantrine in 2001 and 2002 indicated that AL
was effective for treating uncomplicated malaria in northern KwaZulu-Natal [1, 11, 12].
Since 2002, however, there have been no further studies in KwaZulu-Natal, or South
Africa, of the continuing therapeutic effectiveness of AL in the treatment of
uncomplicated malaria. The WHO recommends routinely monitoring antimalarial
resistance at least every three years, and a change in antimalarial medicine if the
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treatment failure proportion ≥ 10% by day 28, or the last day of follow-up if longer than
28 days [8, 30].
Pharmacology of artemether-lumefantrine
Artemether-lumefantrine is a combination of artemether and lumefantrine manufactured
as Coartem® by Novartis: 20mg artemether and 120mg lumefantrine in tablet form [31].
The two drugs act in a complementary manner [32]. Artemether and its active
metabolite, dihydroartemisin, rapidly kill most malaria parasites, while lumefantrine
clears the remainder more slowly [32, 33]. As most parasites are killed by artemether,
the likelihood of selecting resistant parasites to the partner drug, lumefantrine, is much
reduced [32, 33]. Artemether is rapidly absorbed and metabolized, with a half-life of
about two hours, whereas lumefantrine is absorbed more slowly and has a half-life of 3-
4 days in malaria patients [32, 33].
Coartem® is taken as a six-dose oral regimen over 3 days [31]. The dosage depends
upon the weight and age of the patient [31]. The adult dosage for persons aged 12 years
or more, or children weighing 35kg and above, is four tablets as a single dose at the
time of initial diagnosis, 4 tablets after 8 hours, and then 4 tablets twice daily on each of
the following two days [31]. It is recommended that the tablets are taken with fatty food
or milk to improve absorption [31-33].
Recommended protocol and follow-up period for antimalarial efficacy
testing
The WHO protocol for assessment of clinical and parasitological response to
antimalarial medication recommends patient assessment on days 0 (enrolment), 2, 3, 7,
14, 21, and 28. A 28 day follow-up is adequate for drugs with an elimination half-life of
less than 7 days (such as lumefantrine) [30]. A longer follow-up is needed for drugs
with a longer elimination half-life, such as mefloquine [34] and piperaquine [35] which
require 42 days of follow-up [30, 36].
Inadequate responses to antimalarial treatment are classified as: ‘Early Treatment
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Failure (ETF)’ in which there are danger signs or failure to reduce parasitaemia levels
by day 3; ‘Late Clinical Failure (LCF)’ in which there are danger signs or parasitaemia
and fever between days 4 and 28, and ‘Late Parasitological Failure (LPF)’ in which
there is parasitaemia without fever between days 4 and 28 [30]. ‘Adequate Clinical and
Parasitological Response (ACPR)’ is defined as absence of parasitaemia on day 28 in
patients who did not suffer any of the other inadequate responses to treatment [30]. It is
noted that a longer follow-up period increases the losses, reducing a study’s validity;
however no similar comment is made about the number of return visits already required
of patients with the present WHO protocols [30]. From these definitions it may be
inferred that clinically assessing and testing a subject on day 28 should detect Late
Clinical Failure and Late Parasitological Failure.
Molecular markers of malaria resistance
According to the 2002 WHO report, molecular markers may assist in clarifying the
resistance situation [37]. Markers of resistance have been validated for a number of
monotherapies including chloroquine [38] and lumefantrine [39]. The storing of blood
samples on filter paper for future testing as new molecular markers become available is
recommended [37]. Molecular markers may provide warning of developing resistance
to an antimalarial drug in use in an area and give an indication of the persistence of
resistance to a drug that has been withdrawn from an area [37].
At present the genetic basis for artemesinin tolerance or resistance has not been
elucidated, leaving delayed parasite clearance times as the only clear determinant of
artemesinin tolerance and resistance [40], and molecular markers of lumefantrine
resistance as the only markers for resistance for AL.
Certain molecular markers are linked with resistance to lumefantrine, the partner drug in
AL, specifically the pfmdr1 copy number [39], and the mdr186N allele at pfmdr1 codon
86 [41, 42].
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Use of molecular markers to distinguish between re-infection and
recrudescence
A polymerase chain reaction (PCR) test is recommended as mandatory by the WHO to
distinguish between P. falciparum recrudescence and re-infection 7 days or more after
treatment in areas of both low to moderate, and high, transmission [30].
Genotyping of P. falciparum DNA extracted from dried blood spots based on variations
in the genes coding for the glutamine-rich protein and merozoite surface protein 1 and 2
(msp-1, msp-2), may be used to distinguish between different strains of P. falciparum
[43, 44]. The banding patterns of the three molecular markers may be compared before
and after treatment, and if P. falciparum markers are still present, determine if treatment
failure is due to a re-infection or recrudescence of the original infection.
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Recent malaria epidemics in KwaZulu-Natal indicate that effective anti-malarial therapy
is essential for malaria control. Although artemether-lumefantrine has been used as first-
line treatment for uncomplicated Plasmodium falciparum malaria in northern KwaZulu-
Natal since 2001, its efficacy has not been assessed since 2002. The objectives of this
study were to quantify the proportion of patients treated for uncomplicated P.
falciparum malaria with artemether-lumefantrine who failed treatment after 28 days,
and to determine the prevalence of molecular markers associated with artemether-
lumefantrine and chloroquine resistance.
Methods
An observational cohort of 49 symptomatic patients, diagnosed with uncomplicated P.
falciparum malaria by rapid diagnostic test, had blood taken for malaria blood films and
P. falciparum DNA polymerase chain reaction (PCR). Following diagnosis, patients
were treated with artemether-lumefantrine (Coartem®) and invited to return to the health
facility after 28 days for repeat blood film and PCR. All PCR P. falciparum positive
samples were analysed for molecular markers of lumefantrine and chloroquine
resistance.
Results
Of 49 patients recruited on the basis of a positive rapid diagnostic test, only 16 were
confirmed to have P. falciparum by PCR. At follow-up, 14 were PCR-negative for
malaria, one was lost to follow-up and one blood specimen had insufficient blood for a
PCR analysis. All 16 with PCR-confirmed malaria carried a single copy of the multi-
drug resistant (mdr1) gene, and the wild type asparagine allele mdr1 codon 86 (mdr1
86N). Ten of the 16 samples carried the wild type haplotype (CVMNK) at codons 72-76
of the chloroquine resistance transporter gene (pfcrt) ;  three samples carried the
resistant CVIET allele; one carried both the resistant and wild type, and in two samples
the allele could not be analysed.
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Conclusions
The absence of mdr1 gene copy number variation detected in this study suggests
lumefantrine resistance has yet to emerge in KwaZulu-Natal. In addition, data from this
investigation implies the possible re-emergence of chloroquine-sensitive parasites.
Results from this study must be viewed with caution, given the extremely small sample
size. A larger study is needed to accurately determine therapeutic efficacy of
artemether-lumefantrine and resistance marker prevalence. The high proportion of rapid
diagnostic test false-positive results requires further investigation.
Key words: Plasmodium falciparum malaria, artemether, lumefantrine, therapeutic
efficacy, resistance markers, KwaZulu-Natal
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Background
The World Health Organization (WHO) has recommended that drug efficacy be
regularly assessed [1, 2]. Failure to detect the emergence of anti-malarial drug
resistance, could lead to a drug-resistant malaria epidemic, which would have major
public health and economic consequences for an area, province and country. The most
recent malaria epidemics in KwaZulu-Natal, one of three provinces in South Africa with
endemic malaria, were partially attributed to unrecognized resistance to the anti-
malarial therapy being used at the time [3]. Artemether-lumefantrine (AL) has been
first-line treatment of uncomplicated Plasmodium falciparum malaria in northern
KwaZulu-Natal since it was introduced in response to these drug-resistant epidemics in
2001 [4, 5]. Studies should be performed to confirm the continued efficacy of AL, or
provide a warning of emerging resistance, and the need to seek alternative therapy
before a malaria epidemic occurs.
Recent history of Plasmodium falciparum anti-malarial drug resistance in
KwaZulu-Natal
Chloroquine resistance was first detected in KwaZulu-Natal in 1985 [6], and had
increased by 1988 [7], leading to sulfadoxine-pyrimethamine (SP) replacing
chloroquine as the first-line treatment for uncomplicated P. falciparum malaria in
KwaZulu-Natal [4, 8, 9]. SP remained effective until 1996 when malaria incidence
increased sharply in KwaZulu-Natal. Between 1996 and 2000 northern KwaZulu-Natal
suffered increasingly severe malaria epidemics, with more than 40,000 cases reported in
2000 [4, 5, 10].
Only in 2000, were P. falciparum parasites in the region shown to have developed at
least 61% (and as high as 89%, excluding those lost to follow-up) resistance to SP in a
clinical efficacy study, rendering the drug ineffective in northern KwaZulu-Natal [8].
The introduction of AL as the first-line medication for uncomplicated P. falciparum
malaria, together with the reintroduction of DDT insecticide for indoor residual house
spraying in 2001, dramatically reduced malaria incidence in the area [4, 5]. It has been
estimated that the delay in changing first-line treatment for malaria between 1996 and
2000 was responsible for substantial morbidity and mortality, as well as contributing to
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the size of the epidemic [3]. Malaria notifications in KwaZulu-Natal between 1991 and
2011 are shown (Figure 1).
Figure 2: Malaria notifications in KwaZulu-Natal from 1991 to 2011.
Source: Data 1996-2011 - KwaZulu-Natal Department of Health Malaria Control Programme; Data 1991-1995- Knight SE, Anyachebelu EJ, Geddes R, Maharaj R: Impact of delayed introduction of sulfadoxine-pyrimethamine and artemether-lumefantrine on malaria epidemiology in KwaZulu-Natal, South Africa. Trop
Med Int Health 2009, 14:1086-1092
It has been estimated that in 2000, at the height of the epidemic, the malaria incidence
amongst the exposed population in northern KwaZulu-Natal was 5,972 per 100,000 [3].
It should be noted that the malaria notification system became overloaded during these
epidemics, and that the notifications were incomplete. For example during the year 2000
one clinic, Ndumo Clinic, in northern KwaZulu-Natal, saw 30,885 cases based on
laboratory results, a 50-fold increase compared to 1995 [5], and equivalent to 73% of
the total provincial notifications of 42,248 [10].
Artemisinin-based combination therapy (ACT) is advocated for the treatment of
uncomplicated P. falciparum malaria because of the rapid reduction in parasite load
caused by artemisinin or its derivative; the consequent reduced likelihood of resistance
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emerging to the partner drug; the reduction in gametocyte carriage, and rapid clinical
response [11]. ACT is recommended by WHO for the treatment of P. falciparum
malaria [12], and AL is one of the recommended combinations [2, 12]. Studies of AL
therapeutic efficacy in northern KwaZulu-Natal during 2001 and 2002 indicated that AL
was effective for treating uncomplicated malaria in the area [4, 13, 14]. Since 2002,
there have been no further studies of the continuing therapeutic efficacy of AL in
KwaZulu-Natal, or South Africa. The WHO recommends routinely monitoring anti-
malarial resistance at least every three years, and a change in anti-malarial medicine if
the treatment failure proportion is equal to or greater than 10% by day 28, or the last day
of follow-up, if longer than 28 days [1, 12].
Pharmacology of artemether-lumefantrine
Artemether-lumefantrine is a combination of two drugs, artemether and lumefantrine,
manufactured in tablet form as Coartem® by Novartis. Each tablet contains 20 mg
artemether and 120 mg lumefantrine [15]. The two drugs act in an independent but
complementary manner at different stages of the parasite life cycle [16]. Artemether and
its active metabolite, dihydroartemisinin, rapidly kill most circulating malaria parasites,
while lumefantrine clears the remainder more slowly [16, 17]. The probability of
selecting parasites resistant to the partner drug, lumefantrine, is theoretically reduced
due to the small parasite load remaining following activity of artemether [16, 17].
Artemether is rapidly absorbed and metabolized, with a half-life of about two hours,
whereas lumefantrine is absorbed more slowly and has a half-life of 3-4 days in malaria
patients [16, 17].
Coartem® is taken as a six-dose oral regimen over three days. The dosage depends
mainly upon the weight of the patient. The dosage for persons aged 12 years or more, or
younger children weighing 35 kg and above, is four tablets as a single dose at the time
of initial diagnosis, four tablets after eight hours, and then four tablets twice daily on
each of the following two days [15]. It is recommended that the tablets are taken with
fatty food or milk to improve absorption [15, 17, 18].
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Choice of follow-up period for anti-malarial efficacy testing
In the 2009, WHO anti-malarial drug efficacy testing guide [1], inadequate responses to
anti-malarial treatment are classified as: ‘early treatment failure’ in which there are
danger signs or failure to reduce parasitaemia levels by day 3; ‘late clinical failure’ in
which there are danger signs or parasitaemia and fever occurring between days 4 and
28, and ‘late parasitological failure’ in which there is parasitaemia without fever
between days 4 and 28. ‘adequate clinical and parasitological response’ is the absence
of parasitaemia on day 28 (or day 42 for longer acting drugs), irrespective of axillary
temperature, in patients who did not previously meet any of the criteria of early
treatment failure, late clinical failure or late parasitological failure. For drugs with a
half-life of less than seven days, such as artemisinin and lumefantrine, evaluation of
clinical and parasitological response up to 28 days is recommended [1]. For those with
longer half-lives such as mefloquine (three weeks [19]) and piperaquine (two to three
weeks [20]), a follow-up of 42 days is recommended [1, 12, 21].
Although there has been no anecdotal evidence of resistance to AL in KwaZulu-Natal
since its implementation, artemisinin resistance, characterised by slow clearing of
parasite has been confirmed in South East Asia [22], and suggested in Kenya [23].
Previous research by Roper and colleagues demonstrated that SP resistance spread to
southern Africa from East Africa [24]. In neighbouring Mozambique increase in
prevalence of molecular markers associated with lumefantrine resistance since initial
use of AL suggest the need for continued surveillance for the emergence of resistance to
the drug [25]. The primary objective of this study was to screen for late AL clinical and
parasitological failure, the first indication of emerging resistance to AL in South Africa.
Requiring patients to return a clinic six or seven times in one month for assessment
requires considerable resources and the risk of drop-out from the study is high. A single
follow-up assessment at 28 days was therefore chosen which required a patient to return
only once. PCR is recommended by the WHO to distinguish between P. falciparum
recrudescence and re-infection seven days or more after treatment in areas of both low
to moderate, and high, transmission [1].
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Molecular markers of malaria resistance
According to the 2002 WHO report [26], molecular markers may assist in determining
resistance and provide an early warning of developing drug resistance before it becomes
clinically apparent. Markers of resistance have been validated for a number of
monotherapies, including chloroquine [27] and lumefantrine [28]. As the genetic basis
for artemisinin resistance is not known, efficacy of AL is assessed by determining the
molecular markers of resistance for the partner drug, lumefantrine.  Certain molecular
markers have been linked with resistance to lumefantrine, the partner drug in AL,
namely the P. falciparum multidrug resistant (mdr)1 gene copy number [28], and the
mdr186N allele [29, 30]. Multiple copies of the mdr1 gene has been linked with
lumefantrine resistance in Southeast Asia [28], while mutations at the codon 86 of the
mdr1 gene modulate lumefantrine efficacy [31].
Storage of blood samples on filter paper for future testing as new molecular markers
become available is recommended [26].
Ethical issues
The study was approved by the University of KwaZulu-Natal Biomedical Research
Ethics Committee, and by the Health Research Committee of the KwaZulu-Natal
Department of Health.
Methods
The study population included symptomatic persons presenting to health facilities,
diagnosed with uncomplicated P. falciparum malaria in Umkhanyakude Health District,
northern KwaZulu-Natal, using the P. falciparum malaria rapid diagnostic test (First
Response, malaria antigen P. falciparum (HRP2) detection rapid card test manufactured
by Premier Medical Corporation Limited, Kachigam, Daman (UT) 396215, India).
Inclusion criteria
Symptomatic patients aged from five years to 69 years, self presenting to health
facilities, diagnosed with uncomplicated malaria in Umkhanyakude Health District
between January and May 2012, were invited to participate in the study.
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Exclusion criteria
Patients with the following danger signs or symptoms of severe malaria: unable to
drink; vomiting everything; a convulsion during previous seven days; lethargic or
decreased level of consciousness; unable to stand or sit [32], were excluded. Pregnant
women, patients aged less than five years and more than 69 years, and patients treated
for malaria during the previous two weeks were also excluded.
Information provided
At recruitment patients were provided with an information sheet in English and isiZulu
detailing the purpose of the study, which was also explained verbally. Patient queries
were answered after which they were invited to provide written consent.
Investigations
Finger-prick blood spots blotted on to Guthrie 903 filter paper cards (Munktell GmbH,
Barenstien, Germany), and blood samples were collected from all participants for
molecular analysis and malaria microscopy. The patient was then asked to return in four
weeks for repeat malaria film microscopy and blood spot collection, with the offer of
ZAR50 (US$5.79) in travelling expenses upon return. RDT was not performed at
follow-up due to persistence of histidine-rich protein, HRP-2, in patients for as long as
28 days after parasite clearance [14, 33]. Blood spots taken by nurses were sent to the
investigator at the local hospital. These were then collected by the Principal
Investigator, usually twice per month, and posted to the researcher performing the
molecular analysis more than 400 km away.
Thick and thin blood films were prepared according to the National Health Laboratory
Service standard operating procedure for processing specimens for malaria parasites
[34]. Slides were stained using the rapid modified Wright-Giemsa stain (Rapidiff); thin
films being fixed with methanol before staining. Parasitaemia was calculated from the
percentage of red cells containing malaria parasites observed in 10 microscope fields
using the 100x lens.
Parasite DNA was extracted from all blood spots using the QIAamp DNA Mini Kit
(QIAGEN, Whitehead Scientific). The extracted DNA was then subjected to
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quantitative real-time PCR (qPCR) and nested PCR analysis to confirm the presence of
P. falciparum parasites [35, 36].
All samples confirmed as P. falciparum positive by PCR, were subjected to mutational
analysis to detect the prevalence of molecular markers linked with resistance to
lumefantrine, (mdr1 gene copy number amplification) and chloroquine (mutations at
mdr1 codon 86, [27] and codons 72 to 76 of the chloroquine resistance transporter (crt)
gene ) [37]. At the follow-up visit, the patient was clinically assessed, and a further
finger prick blood sample taken for P. falciparum PCR and blood film.
Results
A total of 49 patients with a diagnosis of malaria based on a rapid diagnostic test were
enrolled in the study. Two patients did not have their age recorded. The age range of the
remaining 47 patients was 2 – 69 years; median 15 years, and mean 21.1 years. The
largest group comprised those less than 10 years of age (Figure 2). Four patients were
less than minimum age of five years stipulated in the study protocol. Their treatment,
however, was identical to that in the National Treatment Guidelines [38], and they were
included in the analysis.
23
Figure 3: Age and gender of patients with malaria RDT-positive recruited from Umkhanyakude Health District,January to May 2012 (N=47)
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Confirmation of Plasmodium falciparum malaria by PCR
Only 33% (16/49) patients were confirmed to have P. falciparum malaria by PCR
(Figure 3).
Figure 4: Age and gender of patients with P. falciparum malaria confirmed by PCR recruited fromUmkhanyakude Health District, January to May 2012 (N=16)
Closer inspection of the RDTs revealed that frequently too much blood had been used,
rendering the test virtually impossible to interpret. The age range of those confirmed
with P. falciparum was 2 - 40 years with median age 14.5 years and mean 16.8 years.
Nearly half (7/16) of those with PCR-confirmed malaria were aged less than 10 years.
Results for the P. falciparum PCR positive patients are summarized in Table 1.
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40 Female Mozambique 36.5 1(sensitive)
Asparagine
(mdr1 86N -
sensitive) CVMNK(sensitive) 28 Negative
7 Male Not recorded 39.4 1 asparagine
CVMNK and
CVIET(resistant) 191 Negative
32 Female None 36.4 1 asparagine CVIET 168
Insufficient
sample
24 Male None 39.3 1 asparagine CVMNK 49 Negative
9 Female Not recorded
Not
recorded 1 asparagine CVMNK 29 Negative
31 Male Mozambique 38.3 1 asparagine CVMNK 32 Negative
8 Female None 36.7 1 asparagine CVIET 29 Negative
15 Male Mozambique 38.0 1 asparagine CVIET 106 Negative
20 Male Mozambique 41.0 1 asparagine CVMNK 127 Negative
37 Female Not recorded 38.7 1 asparagine CVMNK 86 Negative
6 Female None 39.0 1 asparagine CVMNK 28 Negative
2 Female Mozambique
Not





17 Male None 38.2 1 asparagine CVMNK 69 Negative
14 Female None 38.0 1 asparagine Not obtained 92 Negative
4 Female Mozambique 38.0 1 asparagine CVMNK 59 Negative
3 Male Not recorded 38.0 1 asparagine Not obtained 57 Negative
Presence of fever
Fever (auxiliary temperature ≥37.5°C) was recorded in 64% (27/42) of all patients who
were initially diagnosed with malaria and 77% (11/14) of the PCR malaria confirmed
cases, while 57% (16/28) of those PCR negative had a fever. Temperature was not
recorded for two malaria PCR positive patients.
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Recent travel
Six of the 16 PCR malaria-confirmed cases reported having travelled to Mozambique
within the previous month.
Blood films
Due to liaison difficulties with a local laboratory, blood films were only obtained in
15/49 recruited patients, examined by the hospital laboratory technicians. Of those, only
four were PCR-confirmed malaria samples, and of those four, one was P. falciparum
positive by microscopy with a parasitaemia of 0.25%. All other 14 blood films were
microscopy-negative for P. falciparum.
Molecular markers
All 16 PCR P. falciparum positive samples collected at enrolment had a single copy of
the mdr1 gene and carried the wild type asparagine allele at codon 86 of the mdr1 gene
(mdr1 86N) (Table 1). Results for 14 of the 16 samples were crt 72-76 genotyped. Ten
samples carried the wild chloroquine sensitive haplotype (CVMNK), three the pure
mutant haplotype (CVIET) associated with chloroquine treatment failure, while one
carried both wild and mutant alleles. Two samples proved inadequate for crt
genotyping.
Follow-up
Only 14% (7/49) of the patients returned for follow-up, of which six were P. falciparum
PCR positive at enrolment. Malaria control personnel tracked down and obtained blood
specimens for follow-up PCR from a further nine non-returning PCR-confirmed
patients, at varying intervals from four weeks following recruitment. Of the initial PCR
positive cohort, 14 were found to be negative at follow-up, one sample contained
insufficient blood for testing and one patient was lost to follow-up.
27
Discussion
The primary aim of this study was to assess the therapeutic efficacy of AL, the current
first-line treatment of uncomplicated P. falciparum malaria in northern KwaZulu-Natal.
The study was hampered by a scarcity of diagnosed malaria cases. Of 49 patients
enrolled in the study on the basis of a positive P. falciparum rapid diagnostic test, only
16 were subsequently confirmed to have P. falciparum malaria by PCR analysis.
Amplification of mdr1 gene copy number associated with lumefantrine resistance in
South East Asia was not detected in this study [39]. This result confirms the research
findings in neighbouring Mozambique [25], where no variation in mdr1 copy number
was observed following two years of AL deployment, and supports the hypothesis that
mdr1 amplification is rare in Africa [31].
The mdr1N86Y mutation associated with chloroquine resistance [27] was completely
absent in this study. This finding together with the high prevalence of the crt 72-76 wild
type haplotype (CVMNK) in the study area suggests AL deployment removed
chloroquine drug pressure, allowing chloroquine sensitive parasites to re-emerge as seen
in Malawi [40] and Mozambique [25].  This return of parasite sensitivity to chloroquine
could result in the re-introduction of chloroquine in combination with a partner drug as
an anti-malarial.
All follow-up samples were PCR negative for P. falciparum, implying sustained AL
efficacy, 11 years after it was initially rolled out in KwaZulu-Natal. On a cautionary
note, the high mdr186N allele prevalence is a cause for some concern.  It has been
suggested that increases in mdr186N prevalence is the first step towards lumefantrine
tolerance [30]. Sustained lumefantrine drug pressure is probably driving the selection of
the mdr186N allele in KwaZulu-Natal.  In contrast, the removal of chloroquine drug
pressure probably selected for this allele in Mozambique [25].  Given the wide use of
AL in southern Africa and the high prevalence of resistance markers associated with
lumefantrine resistance, close monitoring of AL efficacy and lumefantrine resistance
markers is recommended to ensure effective first-line treatments are available.
28
Positive study outcomes
Despite the extremely small sample, some valuable data was produced by this study.
Blood spots for molecular analysis
In a low malaria-incidence setting, blood spot samples proved to be a good source for
molecular analysis. Collection of the filter paper samples was relatively easy and
inexpensive. Once collected and correctly stored the samples were resilient to delays in
collection and transport. PCR is capable of detecting malaria parasites at a density of
five parasites per microlitre, whereas thick film microscopy is only reliable at a density
of 50 parasites per microlitre, meaning PCR is more than ten times more sensitive than
microscopy for the diagnosis of malaria parasitaemia [41, 42]. PCR also has a
specificity of nearly 100% for both P. falciparum and P. vivax [43].
Monitoring molecular markers of drug resistance, while a less rigorous method of
assessing drug efficacy than in vivo sensitivity studies, is much less expensive and time
consuming, and is a reasonable method of surveillance for emerging drug resistance
[25]. The WHO recommends that in countries with very low levels of transmission,
such as South Africa, studies of molecular markers of resistance should be conducted
every year [1]. Molecular markers in 10 of the 14 available blood specimens indicated
sensitivity to chloroquine, suggesting that chloroquine resistance may have decreased
following removal of the selection pressure from using chloroquine as first-line therapy.
Similar findings have been demonstrated in neighbouring Mozambique and been
attributed to the withdrawal of chloroquine [25].
Study limitations
Enrolment procedure and administration
The incidence of malaria in the study area remained low during the study period and
cases were geographically scattered, presenting to several different clinics and hospitals
in Umkhanyakude District. Management and control of the patient records and
specimens was difficult. The cooperation of healthcare workers from several health
facilities was required and consistency of the enrolment procedure was difficult to
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achieve. Blood was sent by clinic nurses to the local hospital laboratory which declined
to perform blood films on many patients.
Of the 49 recruited patients only 16 were PCR confirmed malaria. The high proportion
of false positive RDT results was probably mainly due to incorrect use of the test,
indicating a lack of familiarity, and the need for more training. It is possible that false
positive RDT results have erroneously inflated the notified malaria cases in the district
for some time, and is deserving of further investigation.
Sample size
The study aimed to obtain a sample size of 50, which is the minimum recommended by
the WHO regardless of rates of failure anticipated, in order to be representative [1].
However, this study could only include the malaria cases available. In an area which
suffered severe malaria epidemics within the past 12 years, partly attributable to a lack
of parasite resistance data required for upgrading antimalarial treatment policy [3], it is
important to undertake regular drug resistance monitoring, or risk repeating the mistakes
of the past. The last published malaria resistance studies in KwaZulu-Natal took place in
2002 [4, 14], and the data in this study could be used to inform a larger study.
Follow-up
Despite the financial incentive offered to recompense for travelling expenses, most
patients had to be tracked down by malaria control personnel at varying time intervals
after treatment.
Use of single follow-up visit
Use of a single follow-up visit on day 28, rather than follow-up visits on days 1,2,3,7,14
and 28, as recommended by the WHO [1, 26, 32], meant that in the event of persistence
of P. falciparum parasitaemia by day 28, it would not be possible to distinguish between
early treatment failure, late clinical failure, and late parasitological failure. The finding
of persistence of parasitaemia by day 28 would provide a motivation for a further study
following the WHO protocol [1] to distinguish the degree of resistance. However, as
already mentioned, persuading patients to return for six follow-up visits is not easy,
evidenced by the difficulty faced in this study of obtaining even a single follow-up from
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patients. The single 28 day follow-up should detect most clinical and treatment failures,
and seems particularly suitable for screening for late clinical failure and late
parasitological failure.
Conclusions
Determining drug efficacy,  particularly as malaria transmission approaches zero, is
critical, as the last remaining parasites are most likely the most resistant [44].  Since
therapeutic efficacy of AL in KwaZulu-Natal had not been assessed recently, this study
attempted to address the issue.  Unfortunately the extremely low incidence of malaria in
northern KwaZulu-Natal impacted negatively on patient recruitment. As drug efficacy
data is essential to inform policy, particularly as South Africa embarks on an
elimination agenda [45], every attempt to obtain robust valid resistance data must be
made.  Future options include larger studies across multiple sites, and the follow-up of
all malaria cases at 28 days with annual molecular marker studies [1].
Although 49 patients were recruited into the study based on RDT results, only 16 were
confirmed P. falciparum positive by PCR.  Preliminary investigations appear to indicate
that incorrect use of RDT was the principal reason for the high proportion of false-
positive results.  Since definitive diagnosis is a fundamental tenet of the elimination
agenda, further investigation into the cause of the false-positive RDT results is
indicated, and corrective measures put in place to prevent misdiagnosis.
Despite the small sample size, all samples were malaria negative at Day 28, or longer,
suggesting sustained AL efficacy in KwaZulu-Natal.  Support for this is provided by the
absence of mdr1 copy number amplification found in this study. However rigorous
regular lumefantrine resistance monitoring is recommended given the high prevalence
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CHAPTER IV: DISCUSSION, CONCLUSION AND
RECOMMENDATIONS
Introduction
In this chapter the lessons learned from the research will be discussed. Some issues have
already been mentioned in the paper submitted for publication in the previous chapter;
however in addition the practical challenges and lessons learned will be expanded upon.
Therapeutic efficacy of artemether-lumefantrine
The study found no definite evidence, either clinically or from molecular marker
analysis, of resistance to artemether-lumefantrine, providing some reassurance that the
drug is still efficacious, and that there is, as yet, no evidence of a need to change first
line therapy for the treatment of uncomplicated malaria in northern KwaZulu-Natal.
None of the 14 confirmed P. falciparum patients followed up were P. falciparum PCR
positive at a follow-up. Nor did any of the 16 confirmed P. falciparum PCR-positive
patients show an increase in the pfmdr1 copy number associated with lumefantrine
resistance [45]. A slight concern is that all 16 samples carried the mdr186N (asparagine)
allele. Although this means that there was no mdr186Y allele associated with
chloroquine resistance [38], an increase in the frequency of the mdr186N allele has been
suggested as a step towards lumefantrine tolerance [42] . As mentioned already, the
final sample was very small, meaning that the results must be treated with caution.
Use of blood spots for PCR analysis
The study demonstrated the robustness of PCR analysis of blood spots as an
investigative tool, in a rural area with staff unfamiliar with research. Blood spots for
PCR are routinely used for the detection of HIV in exposed infants [46]. The study
blood spots were easy to obtain, and resilient to delay in transport to the laboratory more
than 400km away. PCR is capable of detecting malaria parasites at a density of five
parasites per microlitre or less [47, 48], whereas thick film microscopy is only reliable
at a density of 50 parasites per micro litre or more [48]. PCR has also been shown to
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have a specificity approaching 100% for both P. falciparum and P. vivax [49]. Ideally
blood spots should be obtained from all P. falciparum cases in KwaZulu-Natal, while
the present low malaria incidence persists so that a continuous molecular marker
surveillance may be carried out [30].
Challenges
The study encountered a number of challenges:
Malaria incidence
The incidence of malaria in the study area remained low during the study period, which
severely hampered the research project. Too low a malaria incidence to research was a
gamble taken when the study was embarked upon. However, in 2011 there were
circumstances which suggested that malaria incidence in 2012 could be sufficient to
undertake the research.
District Hospitals in northern Umkhanyakude District had reported a surge in cases in
early 2011. Malaria Control Programme statistics showed 84 ‘passive’ (reported by
health institutions) cases for Jozini and Umhlabuyalingana Districts in northern
KwaZulu-Natal for the period January to June 2011. Total active (cases actively sought
out by the Malaria Control Programme) and passive cases in the two sub-districts for
2011 were 153, compared to 72 in 2010.
In addition to this apparent increase in malaria cases in 2011 compared to 2010, it
appeared that malaria control measures in neighbouring southern Mozambique were
deteriorating. Insecticide spraying in southern Mozambique has been one of the highly
successful malaria control measures undertaken by the Lubombo Spatial Development
Initiative implemented since 2000 [50] . However, it was reported at a meeting on 28
September 2011 between a Mozambiquan delegation from Maputo Province and a
delegation from the KwaZulu-Natal Department of Health, that there was no funding to
continue the insecticide spraying. A resulting resurgence of malaria in southern
Mozambique would be likely to spill over into northern KwaZulu-Natal.
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In the event, and revealed partly as a result of the research project, it appears that many
of the reported ‘passive cases’ may have been incorrectly diagnosed. Active cases are
diagnosed by microscopy and blood films obtained by Malaria Control Programme
personnel. The field workers in Northern KwaZulu-Natal (Jozini and Umhlabuyalingana
Sub-districts) obtain approximately 2000 blood films per month in the high risk
Mozambiquan border area, targeting symptomatic persons and contacts of confirmed
cases on which malaria microscopy is performed. For the period January to May in
2011, four positive P. falciparum cases were identified between the two sub districts,
and in 2012, nine cases were diagnosed. In contrast, ‘passive cases’ are those cases
presenting to health facilities and diagnosed by the health facility, usually by rapid
diagnostic test (RDT). For the period January to May 2011, 87 passive cases were
reported, and for the same period in 2012, 96 passive cases were reported. These
statistics show many more ‘passive’ cases are reported, based on RDT diagnosis, than
‘active’ cases diagnosed by microscopy. From the large number of false positive rapid
test results found during the study, it would appear that RDT- diagnosed passive cases
may contain many false positive results, supported by the persistently low number of
cases diagnosed by active surveillance. From the Malaria Control Programme statistics
it seems unlikely that there were a substantial number of cases missed by the study, and
that the incidence of malaria really was low.
False positive rapid diagnostic test results
The finding that 33/49 patients were diagnosed falsely positive by RDT was a major
hindrance and disappointment in the conduct of the study. At one stage of the study a
particular clinic was enrolling a surprisingly large number of patients, which prompted
Malaria Control Personnel to visit the clinic to investigate a possible outbreak. It turned
out that one nurse at the clinic was putting far too much blood onto the rapid tests such
as to make them uninterpretable. Some of these tests are shown in figure 4, lined up
below correctly used tests for comparison. It should be noted that not all false positive
RDTs came from the one clinic, which indicates that they were not all due to misuse by
one nurse.
The product leaflet of the RDT used claims 100% sensitivity and specificity compared
to an in house group of samples [51]. The WHO rates the First Response® RDT as
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100% sensitive at 200 parasites per μl, with only 3% false positive results, equivalent to
97% specificity [52]. With low malaria incidence a poor predictive value of a positive
RDT is quite possible, even with a specificity as high as 97%. It would never-the-less
appear that there is a need for further education and training regarding the use of
malaria RDTs in the District.
Figure 5: Rapid Diagnostic Tests from Study
Enrolment and administration
This low malaria incidence resulted in cases occurring in a scattered distribution and
patients presenting to several different clinics and hospitals within the district. Neither
the Principal Investigator, nor even any of his co-authors were able to personally enrol
patients and prepare blood films for review by Malaria Control Laboratory staff, as
originally envisaged. To assist with patient enrolment, nurses from several health clinics
were recruited to assist the study; however consistency of the enrolment procedure was
difficult to achieve, with several different staff involved, each enrolling only a small
number of cases.
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Most blood samples for malaria film and blood counts were sent by clinic nurses to one
local hospital laboratory with whom co-operation was not fully achieved, meaning that
blood counts and blood films on many patients were not performed. One reason for the
difficulty with the laboratory seems to have been that instead of simply filling in the
laboratory request form in the usual way, the nurses were writing headings such as
‘Malaria Research’ on the forms, which seems to have contributed to the samples being
disowned by the laboratory staff. This was a difficulty not anticipated, as the Head of
District National Health Laboratory Services had been consulted and given approval,
and the tests requested were nothing more than usual for a case of malaria. Also, the
onsite Medical Manager was a co-investigator. It had been hoped that it would be
possible for one of the investigators to personally make the blood films and bring them
back for microscopy by the Malaria Research Programme, however the scarcity and
scattering of cases prevented this. In hindsight greater consultation should have taken
place with the individual hospital laboratory managers, especially when it became
apparent that cases would be scattered and sporadic, and that blood films could only be
done on samples sent from clinics or hospitals. This unforeseen difficulty also illustrates
that once incidence of malaria incidence decreases to a low level, interest in malaria
amongst healthcare workers and public may also decrease. Laboratories may become
less likely to have the reagents necessary to prepare malaria films, and instead rely
entirely on rapid diagnostic tests. It should be noted that the National Guidelines for the
Treatment of Malaria [3], recommend either a rapid diagnostic test or microscopy of
blood smear.
A number of other administrative difficulties occurred. Initially clinic nurses were
advised to keep completed recruitment forms at the clinic, sending only the blood spots,
and submitting all forms together upon the return of the patient for follow up. This
system was quickly found to be ineffective, as most patients did not return for follow-
up. After the first few patients, nurses were requested to submit the enrolment form with
the enrolment blood spots taken for PCR and molecular markers. This lessened the
likelihood of the enrolment form being lost, and through the information on place of
residence, patients who did not return for follow-up could be tracked down by Malaria
Control personnel.
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Four children were recruited into the study below the stipulated minimum age of 5
years. The author had decided to set this age limit for a combination of reasons,
including possible difficulty in swallowing tablets with younger children, which might
affect the efficacy results. Malaria is an unpredictable, potentially lethal disease, even if
treated correctly at an early stage, and although the study involved no change to the
standard treatment, the author was reluctant to include very young children in the study.
However the WHO specifically recommends efficacy trials to include children younger
than 5 years [37, 53]. In the event younger children were included due to
misunderstanding of the recruiting nurses. Once recruited, and treated, and with the
small number of proven cases, there appeared to be no disadvantage to the children
involved, not to include their results, and their data was valuable. The follow-up, which
would be less likely to occur outside the study, could be to their advantage.
The study could only include the malaria cases available, and it should also be noted
that had a sample of even this small size been used to audit therapeutic efficacy of
sulfadoxine-pyrimethamine in 1998 or 1999 in KwaZulu-Natal, it would probably have
demonstrated the need to change first line medication earlier than in 2000.
Monitoring molecular markers of drug resistance, while a less rigorous method of
assessing drug efficacy than in vivo sensitivity studies, is much less expensive and time
consuming, and is a reasonable method of surveillance for emerging drug resistance
[54]. The WHO recommends that in countries with very low transmission, such as
South Africa, studies of molecular markers of resistance should be conducted every
year. Most of the specimens (10/14) from molecular markers appeared to be sensitive to
chloroquine. This suggests that chloroquine resistance may have decreased following
removal of selection pressure from chloroquine, as has been demonstrated in
neighbouring Mozambique [54] .
Single follow-up visit
The standard WHO protocol for assessment of antimalarial drug efficacy demands at
least 6 follow-up visits [30]. Use of one follow-up at 28 days, or longer for drugs with
longer half-lives, means that it is not possible to distinguish between the different
classifications of failed response to treatment (early treatment failure, late clinical
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failure, and late parasitological failure [30]). However none-the-less it would be
expected that all the types of treatment failure would show parasites at the final follow-
up, so a 28 day follow-up should be an effective tool for screening for parasite
resistance, especially in the early stages of development of resistance. The difficulty of
achieving multiple follow-up visits without a large drop-out rate seems to be
underplayed in the protocol literature, although the large amounts of time, labour and
money required have been noted [54]. In this study only 7/49 subjects returned for
follow-up. They were mostly recruited from a rural area covered by a District Hospital
more than 100km from the District Office where the author and Malaria Control
Programme were based. Blood spots had to be first sent to the local hospital, and then
usually collected by the author every two weeks, who would post them to Durban for
analysis. This meant that with delay in samples being sent to the local hospital,
combined with the collection interval from the hospital, it could take a month before it
could be definitely ascertained that a patient had not returned. Malaria Control
Programme personnel were then asked to trace the subject, which could also take time,
as the subject was not always at home. It had not originally been envisaged that it would
be practical to conduct any study with only the few scattered cases that finally
presented.
In the opinion of the author the arduous protocol for the surveillance of the therapeutic
efficacy of antimalarial medicines [30] is one factor in the lack of resistance data
available in South Africa, and probably many other malarious areas of the world. There
appears to be a need for a much simpler WHO-approved antimalarial resistance
screening tool, such as the method used in this study.
Conclusions
This study found no definite evidence, either from follow-up after treatment, or
molecular markers, of acquired P. falciparum resistance to artemether-lumefantrine in
northern KwaZulu-Natal. Molecular markers also suggested that most cases of P.
falciparum malaria would be sensitive to chloroquine.
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Recommendations
South Africa is committed to the goal of malaria elimination [55]. With very low
malaria incidence, as is presently the situation in northern KwaZulu-Natal, with an
average of only one microscopically confirmed active surveillance case per month,
according to KZN Malaria Control Programme statistics, drug resistance marker studies
should be undertaken annually, and all cases of P. falciparum malaria should be
followed up at 28 days, as recommended by the WHO [30]. Another option is to pool
data from several sites to obtain a sample large enough to be statistically significant,
although this method could be at the expense of being able to determine resistance
patterns in specific localities. Use of PCR to confirm diagnosis and for follow-up
monitoring provides an effective alternative to microscopy which may be easier to use
in a rural setting, but requires adequate technical expertise and resources.
Further research
As well as continuing ongoing surveillance of antimalarial drug efficacy, further
research appears to be needed into the reliability of ‘passive’ malaria cases reported by
health institutions in northern KwaZulu-Natal, mainly on the basis of rapid tests. The
study found a high false-positive proportion of cases reported by clinics, at least partly
due to incorrect use of rapid tests. The difference in magnitude of ‘passive’ cases
diagnosed by rapid tests and ‘active’ cases diagnosed by microscopy since at least 2010
in northern KwaZulu-Natal, suggests persistent over-diagnosis by health institutions for
some time, and a possible chronic over-estimate of malaria incidence.
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The recent history of malaria epidemics in northern KwaZulu-Natal shows that resistance to the
standard malaria treatment may arise quickly and contribute to epidemics. Artemether-
lumefantrine has now been used for 10 years as the first line treatment for uncomplicated P.
falciparum malaria, but has not been assessed for therapeutic efficacy for 9 years.
Purpose
The purpose of the study is to assess the therapeutic efficacy of artemether-lumefantrine for
patients with uncomplicated malaria in Umkhanyakude Health District in 2011-12, and test for
molecular markers of antimalarial drug resistance.
Objectives
The main objective is to quantify the failure proportion after 28 days of a sample of patients
treated for uncomplicated malaria with artemether-lumefantrine. Molecular analysis of blood
samples will search for molecular markers of resistance to artemether-lumefantrine and
chloroquine.
Study design
The study will be an observational cohort.
Settings
The study will take place in 3 hospitals, and 28 attached clinics in Umkhanyakude Health
District.
Study population
The study population will be patients with uncomplicated P. falciparum malaria presenting to 3
hospitals and their 28 attached clinics in Umkhanyakude Health District.
Study sample
A sample of between 50 and 100 patients aged between 5 and 69 years with uncomplicated P.
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falciparum malaria will be recruited between September 2011 and May 2012.
Data collection
Patients will be tested for malaria using blood films and blood spots for molecular analysis at
diagnosis and after 28 days. Molecular analysis will also be conducted for markers of
chloroquine and artemether-lumefantrine resistance.
Statistical methods
The failure proportion will be calculated, with 95% confidence intervals. In the event of a
substantial number of failures, association will be sought between failure and parasitaemia
count, age and gender. The proportion of patients with markers for malarial drug resistance will
be calculated with 95% confidence intervals.
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Introduction /background
Artemether-lumefantrine (AL) has been used as the first line treatment of uncomplicated
Plasmodium falciparum malaria in northern KwaZulu-Natal since 2001 [1, 2].
The recent history of malaria epidemics in KwaZulu-Natal indicates that the therapeutic
effectiveness of the anti-malarial medication used to treat patients suffering malaria, together
with the effectiveness at killing mosquitoes of the insecticide used for residual house-spraying,
are vital for malaria control and must be regularly assessed. Failure to do so risks a recurrence
of malaria epidemics, which has major public health and economic consequences for the area
and province as a whole.
A study of the effectiveness of AL should either confirm its’ continuing efficacy or provide a
warning as to the acquisition of resistance by malaria parasites and the need to seek an
alternative therapy before an epidemic occurs.
Literature Review
In 1988, due to the emergence and spread of chloroquine – resistant P. falciparum malaria,
sulfadoxine-pyrimethamine (SP) replaced chloroquine as the first line treatment for
uncomplicated P. falciparum malaria in KwaZulu-Natal [1, 3]. This drug remained effective
until 1996 when malaria incidence began to increase. Between 1996 and 2000 northern
KwaZulu-Natal suffered increasingly severe malaria epidemics with more than 60,000 cases
reported in 2000 [1, 2]. Only in 2000 did a clinical trial, in conjunction with genetic studies,
show that P. falciparum parasites in the region had developed resistance to sulfadoxine-
pyrimethamine, the then recommended first line treatment for malaria, rendering it largely
ineffective in northern KwaZulu-Natal [3]. Subsequently the change of first-line medication to
artemether-lumefantrine, together with change of insecticide used for residual house spraying to
DDT, dramatically reduced malaria incidence in northern KwaZulu-Natal [1, 2]. It has been
estimated that the delay in changing first-line treatment for malaria between 1996 and 2000 was
responsible for substantial morbidity and mortality, as well as contributing to the size of the
epidemic [4]. Artemether combined with lumefantrine is one of the artemesinin-based
combination therapies (ACT) recommended for the treatment of uncomplicated P. falciparum
malaria by the World Health Organization (WHO) [5]. Studies of the therapeutic efficacy of
artemether-lumefantrine in 2001 and 2002 indicated that AL was effective for treating
uncomplicated malaria in northern KwaZulu-Natal [1, 6, 7]. Since 2002, however, there have
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been no further studies in KwaZulu-Natal, or South Africa, of the continuing therapeutic
effectiveness of AL in the treatment of uncomplicated malaria. The WHO recommends
routinely monitoring antimalarial resistance [8], and a change in antimalarial medicine if the
treatment failure proportion ≥ 10% [5].
Pharmacology
Artemether-lumefantrine is a combination of artemether and lumefantrine manufactured as
Coartem® by Novartis: 20mg artemether and 120mg lumefantrine in tablet form [9]. The two
drugs act synergistically. Artemether and its active metabolite, dihydroartemesin, rapidly kill
most malaria parasites, while lumefantrine mops up the remainder more slowly [10]. Artemether
is rapidly absorbed and metabolized, with a half-life of about two hours, whereas lumefantrine
is absorbed more slowly and has a half-life of 3-4 days in malaria patients [10].
Coartem® is taken as a 6 dose oral regimen over 3 days. The dosage depends upon the weight
and age of the patient. The adult dosage for persons aged 12 years or more, or children weighing
35kg and above is four tablets as a single dose at the time of initial diagnosis, 4 tablets after 8
hours, and then 4 tablets twice daily on each of the following two days [9]. It is recommended
that the tablets are taken with fatty food or milk to improve absorption [9].
Choice of follow-up period
A WHO protocol for the assessment of therapeutic efficacy of antimalarial drugs recommends
assessment of patients on days 0, 1, 2, 3, 7 and 14, and defines three categories of therapeutic
response:
 Adequate clinical response
 Early treatment failure – occurring up to day 3
 Late treatment failure, defined as: ‘Development of danger signs or severe malaria in
the presence of parasitaemia on any day from day 4 to 14 without previously meeting
any of the criteria for early treatment failure’ [11].
A more recent WHO report recommends a change in the definition of late treatment failure in
areas of low transmission to:
Presence of parasitaemia on any day from day 4 to day 28 and a measured axillary
temperature of ≥ 37.5°C, without previously meeting any of the criteria of early
treatment failure [12].
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Professor NJ White points out that for rapidly eliminated drugs a 28 day follow-up is needed,
and longer for more slowly eliminated drugs [13]. The 2010 WHO Malaria Treatment
Guidelines recommend at least 28 days follow-up to assess parasitological cure, and 42 days
for regimes containing mefloquine and piperaquine [5].
As yet there has been no anecdotal evidence of resistance to AL in KwaZulu-Natal. Follow-up
malaria films of patients with malaria treated with AL performed by the Malaria Control
Program in 2011 in KwaZulu-Natal have been predominantly negative. The primary objective
of the study is to seek evidence of late clinical failure, which would be the first sign of
resistance to AL. Requiring patients to return for assessment several times requires
considerable resources, and the risk of drop-outs is high.
Considering:
 The 2002 WHO report on monitoring antimalarial drug resistance [12],
 KwaZulu-Natal is presently an area of low malaria transmission;
 The analysis of Professor White [13],
 Lumefantrine, the more slowly eliminated drug in AL has a half-life of a few days, and
not weeks like mefloquine [10], and
 The fact that requiring a patient to return once four weeks later is a fairly simple
request,
a single follow-up assessment at 28 days is chosen.
Purpose of the study
 The purpose of the study is to assess the therapeutic efficacy of artemether-lumefantrine
(AL) for the treatment of uncomplicated P. falciparum malaria in Umkhanyakude
District, northern KwaZulu-Natal in 2011, and to search for molecular markers of drug
resistance.
Specific objectives
The specific objectives are:
 To quantify the proportion of patients treated with artemether-lumefantrine, who fail to
clear P. falciparum from their blood 28 days after treatment
 Test for molecular markers of malarial drug resistance to AL and chloroquine
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 Publish the results
 Use the results to inform policy as to the best choice of drug for the treatment for
uncomplicated malaria in Umkhanyakude District.
Type of research
The research project will be a clinical epidemiological study
Definitions
Early Treatment Failure (ETF) [11]
Development of danger signs or severe malaria on Day 1, Day 2, or Day 3 in the
presence of parasitaemia;
Axillary temperature ≥ 37.5°C on Day 2 with parasitaemia > Day 0 counts;
Axillary temperature ≥ 37.5°C on Day 3 in the presence of parasitaemia, and
Parasitaemia on day 3 ≥ 25% of count on Day 0.
Late Treatment Failure (LTF) [12]
Presence of parasitaemia on any day from day 4 to day 28 and a measured axillary
temperature of ≥ 37.5°C, without previously meeting any of the criteria of early
treatment failure
Late Parasitological Failure [12]
Presence of parasitaemia on any day from Day 7 to Day 28 and axillary temperature
<37.5°C without previously meeting any of the criteria of early treatment failure or late
clinical failure
Danger Signs include
 Not able to drink or breastfeed;
 Vomiting everything;
 Recent history of convulsion;
 Lethargic or unconscious state; and
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 Unable to sit or stand up [11].
Uncomplicated malaria:
Symptomatic infection with malaria parasitaemia without signs of severity and/or evidence
of vital organ dysfunction [5].
Research Methods
Study setting
The study will be set in 3 hospitals and 28 attached clinics in Umkhanyakude District.
Study design
An observational descriptive cohort study design will be used.
Target population
The target population will be persons diagnosed as suffering from uncomplicated P. falciparum
malaria treated with artemether-lumefantrine in KwaZulu-Natal. As malaria drug resistance can
vary considerably between countries and even provinces, the results will only be generalisable
to KwaZulu-Natal.
Study population
The study population will include persons, aged between 5 and 69 years, diagnosed with
uncomplicated P. falciparum malaria in Umkhanyakude Health District, presenting to 3
hospitals or their 28 attached clinics in northern KwaZulu-Natal.
Inclusion / Exclusion criteria
Inclusion criteria:
Patients diagnosed with malaria rapid diagnostic test (RDT) as suffering P. falciparum malaria,
with diagnosis subsequently confirmed by blood film.
Exclusions
The following categories of patients will not be included in the study:
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 Patients with severe or complicated malaria;
 Pregnant women;
 Patients aged less than 5 years and more than 69 years; and
 Patients treated for malaria during the previous two weeks.
Study Sample
Method of selecting sample
As far as possible, all patients, aged 5 years to 69 years, diagnosed with uncomplicated malaria
in Umkhanyakude District between September 2011 and May 2012, will be invited to
participate in the study. Recruitment will cease if 100 patients are recruited. Patients will be
recruited who present to 3 hospitals or the 28 attached clinics. Patients will be attended by either
a doctor or a primary healthcare trained nurse.
Size of sample
An attempt will be made to recruit 100 patients; however the feasibility of recruiting this
number will depend upon the incidence of malaria in Umkhanyakude District. Taking
A 10% failure rate or higher as unacceptable;
Setting the probability of α, a type I error, at 0.05;
Setting the probability of β, a type II error at 0.2;
A minimum of 49 patients will be needed.
Data sources
Measurement instruments / data collection techniques
Patient data will be collected according to a proforma at recruitment.
Blood will be taken at recruitment and follow-up for
o malaria thick and
o thin films,  and
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o molecular analysis.
Genotyping of P. falciparum DNA extracted from dried blood spots based on variations in the
genes coding for the glutamine-rich protein and meroziote surface protein 1 and 2, will be used
to determine if treatment failure is due to a re-infection or recrudescence of the original
infection [14, 15]. Infections will be classified as recrudescent if PCR products for all three
markers from Day 0 and Day of failure parasites are identical. If the banding patterns for any
marker differ between Day 0 and Day of failure parasites, then the infection will be classed as a
re-infection.
This study will assess the prevalence of molecular markers linked with resistance in the partner
drug lumefantrine, specifically the mdr1 copy number [16], and mutations at mdr1 codon 86
[17], since no verified marker for artemisinin resistance exists.
Measures to ensure validity
Internal
All patients will have a blood film made which will be analysed by an experienced
micrcoscopist, and confirmed by another microscopist. Blood spots will also be taken and sent
for malaria polymerase chain reaction (PCR).
A patient will be considered to be infected with P. falciparum malaria if:
 The blood film is definitely positive for P. falciparum, or
 The PCR test is positive.
A borderline blood film with negative PCR will be considered negative.
In the unexpected event of the blood film being clearly positive, but the PCR being negative, the




Effort will be made to reduce the number of follow-up drop outs. Patients will be offered R50 to
assist with travelling expenses when they return for follow-up.
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Selection bias
All eligible persons diagnosed with malaria will be invited to participate in the study
Information bias
Reporting bias:
There will be no discussion of results between the microscopists reporting on blood films and
the technician performing the PCR test.
Detection bias:
Molecular analysis, combined with microscopy, should minimise the number of false negative
results.
External Validity / Generalisability
Pilot study





 Duration of illness
 Other medications
 Travel history within past 60 days
 HIV status ( if already known)
 Home address
 Artemether-lumefantrine dosage given





o P. falciparum malaria rapid diagnostic test result
o Thick blood film for malaria diagnosis
o Thin blood film for malaria diagnosis
o Polymerase chain reaction analysis for P falciparum
o Reinfection/recrudescence assessment using nested PCR
o Assessment of mdr1 copy number (as an indicator of AL resistance)
o Assessment of Chloroquine sensitivity
Plan for Data collection
 A data collection sheet will be completed at enrolment and samples taken for
 28-day follow-up data collection sheet
 Data to be collated in excel spreadsheet
Plan for Data handling/processing
Data to be collated in a Microsoft excel spreadsheet
Statistical methods
Descriptive statistics
The proportion of patients with confirmed uncomplicated P. falciparum malaria, treated with
artemether-lumefantrine, and cleared of parasites by 28 days will be calculated.
The proportion of patients demonstrating molecular markers of resistance to antimalarial drugs
will also be calculated.
Analytic statistics
The 95% confidence interval for failure ratio will be calculated and compared the proposed
maximum 10% acceptable failures.
The 95% confidence interval for the proportion of patients testing positive for markers of
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resistance to antimalarial drugs will also be calculated.
List of possible confounders
The study is not an analytical study with a control group
List of associations to be measured
In the event of sufficient failures to compare with other variables, failure to clear parasites
would be compared to parasitaemia count, age, and gender.
Ethical considerations
Institutional Ethical Review Board
The study will be submitted to the University of KwaZulu-Natal Biomedical Research Ethics
Committee for approval.
Permissions
Permission will be obtained from the District Manager, Umkhanyakude Health District Office,
Jozini, and approval obtained from the KwaZulu-Natal Department of Health Provincial Health
Research Committee.
Informed consent and participant information
All patients aged 18 years or over will be asked to sign a consent form written in English and




Travelling expenses for subjects R50
Molecular cost per sample with test run in duplicate:
Smear/RDT confirmation using qPCR: R35
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Reinfection/recrudescence assessment using nested PCR R30
Assessment of mdr1 copy number R40
Assessment of Chloroquine sensitivity R35
Sample transport costs to Medical Research Council laboratory: R60
Total cost per subject: R250
Total budget if 100 patients recruited: R25,000
Study period / Time lines
It is hoped that recruitment of patients may begin in September 2011. The study will continue
until 100 patients are recruited or until May 2012, whichever is sooner.
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 ACT: artemesinin-based combination therapy
 ETF: early treatment failure
 LFT: late treatment failure
 PCR: polymerase chain reaction
 RDT: rapid diagnostic test
Addenda
Enrolment Data collection sheet
Today's date
Patient information sheet given? Yes    /     No
Patient consent form signed? Yes    /     No
Method of positive malaria diagnosis Rapid Test (RDT)   /   Blood film
Active surveillance case? Yes    /     No




Age (Must be ≥ 5 yrs and < 70 yrs)
Gender Male    /    Female
Date became ill
Other medication
Travel 60 days prior to illness
HIV status, if known
Symptoms of complicated malaria: If any answer: 'Yes', do not enroll in study, but refer to hospital.
Unable to Drink Yes     / No
Vomiting everything Yes     /     No
Convulsion during past 7 days Yes     /     No
Lethargic or decreased consciousness Yes     /     No
Unable to stand or sit Yes     /     No
Pregnant Yes     /     No


















Study samples taken: SA /  Moz / Swaz / Other
Thick film Yes     /     No
Thin film Yes     /     No
Blood spot for molecular analysis Yes     /     No
Return date  (28 days) Yes     /     No
Compiled by
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28 Day follow-up data collection sheet
28 Day follow-up data collection sheet
Today's date
Malaria Rapid Test Result today Pos    /    Neg





Gender Male    /    Female
Date enrolled in study
Symptoms of complicated malaria: If any answer 'Yes', please refer to hospital.
Unable to Drink Yes     /     No
Vomiting everything Yes     /     No
Convulsion during past 7 days Yes     /     No
Lethargic or decreased consciousness Yes     /     No
Unable to stand or sit Yes     /     No






Dose Coartem (tablets bd)
Were all tablets taken as instructed? Yes    /      No
If not, which tablets were taken?
Study samples taken:
Thick film Yes     /     No
Thin film Yes     /     No
Sample for Malaria PCR Yes     /     No
R50 given for travelling expenses, and signed
for? Yes /     No





Patient information sheet (Adults - English)
Dear Sir/Madam,
I am Dr CHV Williams, and work at




Cellphone: 072 584 3472
Email: hervey.williams@kznhealth.gov.za
A blood test shows that you have malaria which can be a serious illness.
Since the year 2001 coartem™ has been used to treat uncomplicated (less severe)
malaria in KwaZulu-Natal. It seems to work well, but we want to check that it is still
curing malaria. We wish to follow-up 100 patients with uncomplicated malaria in
Umkhanyakude District.
We are inviting you help us by letting us take an extra drop of your blood today, to
study the malaria, and to come back for a check-up after 4 weeks, when we will ask for
another drop of blood to confirm the malaria has disappeared.
Your blood will only be used to test for malaria. In this study your treatment will be the
same as for anyone else with malaria. We will just observing you more closely than
usual.
This study has been ethically reviewed and approved by the UKZN Biomedical
Research Ethics Committee (approved number:………….)
In the event of any problems or concerns you may contact Dr CHV Williams at the
above address, or the
Biomedical Research Ethics Committee at
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION
Research Office, Westville Campus Govan Mbeki Building
Private Bag X 54001, Durban 4000
KwaZulu-Natal, SOUTH AFRICA
Tel: 27 31 2604769 - Fax: 27 31 2604609; Email: BREC@ukzn.ac.za
You are not obliged to participate in this study, and are free to change your mind and
withdraw at any time. You will still receive the usual treatment for malaria.
If you return after 4 weeks, we will offer you R50 for traveling expenses.
It is intended to publish the results of the study, however no patient identities will be
revealed. No personal information obtained in the study will be shared with anyone not
involved in the research.
An anonymous dried frozen spot of blood will be kept at the Malaria Research
Programme laboratory of the Medical Research Council in Durban for future malaria
research.
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Patient information sheet adults - Zulu translation
Iphepha lesaziso seziguli ngokuhlolwa kwezinsuku eziwu-28 emva
kokuthatha amaphilisi i-coartemTM eyelapha umalaleveva
Mnumzane/Nkosikazi
Igama lami ngingu Dr CHV Williams, ngisebenza e-Mkhanyakude emnyangweni
wezempilo. Imininingwane yekheli ikanje:
Umkhanyakude Health District Office
Jozini 3969
Izinombolo zocingo: 035 572 1357; 072 584 3472
I-Email: hervey.williams@kznhealth.gov.za
Ukuhlolwa kwegazi  lakho kukhombise ukuthi unomalaleveva okungaba isifo
esinobungozi kakhulu.
Kusukela ngonyaka ka-2001 i-CoaratemTM yasetshenziswa ukwelapha umaleveva
KwaZulu Natal.  Ibonakale isebenza kahle kakhulu, kodwa sisafuna ukuhlola ukhuthi
isaqhubeka nokusebenza kahle ekwelapheni kwalesisifo.
Ebesikucela kuwena ukuba usinikeze imvumo yokuthi sithathe elinye futhi iconsi legazi
lakho namuhla ukuze sizokwazi ukuqhuba lolucwaningo lukamalaleveva egazini lakho.
Uyacelwa futhi ukuba uphinde ubuye emva kwamasonto amane ukuzoqhubeka
nokuhlolelwa lesisifo, lapho-ke sizophinde sikucele futhi ukuba usinikeze enye imvumo
yokuthatha elinye iconsi legazi ukuze siqinisekise ukuthi welapheke ngempela
kumalaleveva.
Igazi lakho lizosetshenziswa ukhuhlolelwa umalaleveva nje kuphela, hhayi okunye.
Kulokhukuhlolwa amaphilisi owatholayo azoqhubeka afane nabobonke abanye
abaphethwe umalaleveva umehluko ukuthi nje wena sizobe sikubheke eduze
kunabanye ngokulokhu sikucela ukuba ubuye njalo emtholampilo uma kudingekile.
Lolu cwaningo luvunyelwe labhekwa ngokwesisekelo sezinkolelo yiUKZN Biomedical
research ethics committee ( inombolo esemtethweni………)
Uma uneminye imibuzo/izinkinga ungangaxhumana noDr CHV Williams kulekheli
elilandelayo:
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION
Research office , Westville campus Govan Mbeki Building
Private Bag X54001, Durban 4000
KwaZulu-Natal, South Africa
Tel: 27 31 2604769-Fax: 27 31 2604609; Email: BREC@ukzn.ac.za
Sifisa ukukwazisa ukuthi awuphoqwanga ukuba yingxenye yalolucwaningo
lokuhlolelwa umalaleveva nokuthi ulokhu ubuya njalo emva kwamasonto amane
ukuzohlolwa emtholampilo . Uma ungathandi ukuba yingxenye yalolucwaningo
uvumelekile ukwenqaba. Noma wenqabile uzoqhubeka ukunikwa amaphilisi okwelapha
umalaleveva njengokwejwayelekile. Uma kumele ubuye emva kwamasonto amane
uzonikezwa imali yokugibela engango R50.
Imiphumela yalolu cwaningo izoshicilelwa, kodwa ayikho imininigwane yomuntu
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ezovezwa. Imininigwane yakho etholakale kulolucwaningo iyimfihlo, angeke ivezelwe
abantu abangangekho emphathini walolucwaningo.
I consi legazi eliqandisiwe lanomawubani lizo bekwa eMalaria Research Programme
laboratory ye Medical research council eThekwini lapho izosetshenziselwa eminye
imicwaningo esikhathini esiphambilini.
 I-coartem okungamaphilisi kamalaleveva kufanele uthathe amaphilisi amane, kabili
ngosuku izinsuku ezintathu. Kumele uyithathe nobisi noma emvakokudla uze uyiqede.
Uma ungayithathanga njengoba uyaliwe maningi amathuba okuthi uphinde uphathwe
umalaleveva futhi.
Uma uzizwa ungabingcono, noma ukugula kuqhubekela phambili emva kwezinsuku
ezimbili, kumele ubuye masinyane emtholampilo noma esibhedlela.
Abakhulelwe, izingane ezingaphansi kweminyaka emihlanu (5) nabadala abangaphezu
kweminyaka engamashumi ayisikhombisa (70) abavumelekile ukuba yingxenye
yalolucwaningo.
Uyacelwa ukuba ubuye ngomhlaka……………………………………………………
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Patient information sheet (Children - English)
Dear Sir/Madam,
I am Dr CHV Williams, and work at




Cellphone: 072 584 3472
Email: hervey.williams@kznhealth.gov.za
A blood test shows that your child has malaria which can be a serious illness.
Since the year 2001 coartem™ has been used to treat uncomplicated (less severe)
malaria in KwaZulu-Natal. It seems to work well, but we want to check that it is still
curing malaria. We wish to follow-up 100 patients with uncomplicated malaria in
Umkhanyakude District.
We are inviting you to help us by letting us take an extra drop of your child’s blood
today, to study the malaria, and to come back for a check-up after 4 weeks, when we
will ask for another drop of blood to confirm the malaria has disappeared.
Your child’s blood will only be used to test for malaria. In this study your child’s
treatment will be the same as for anyone else with malaria. We will just observing your
child more closely than usual.
This study has been ethically reviewed and approved by the UKZN Biomedical
Research Ethics Committee (approved number:………….)
In the event of any problems or concerns you may contact Dr CHV Williams at the
above address, or the
Biomedical Research Ethics Committee at
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION
Research Office, Westville CampusGovan Mbeki Building
Private Bag X 54001, Durban 4000
KwaZulu-Natal, SOUTH AFRICA
Tel: 27 31 2604769 - Fax: 27 31 2604609; Email: BREC@ukzn.ac.za
You are not obliged to have your child participate in this study, and are free to change
your mind and withdraw at any time. Your child will still receive the usual treatment for
malaria.
If you return after 4 weeks, we will offer you R50 for traveling expenses.
It is intended to publish the results of the study, however no patient identities will be
revealed. No personal information obtained in the study will be shared with anyone not
involved in the research.
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An anonymous dried frozen spot of blood will be kept at the Malaria Research
Programme laboratory of the Medical Research Council in Durban for future malaria
research.
Your child should take coartem™ …..tablets, 2 times per day for 3 days, with milk or a
meal, until the pills are finished. Otherwise the malaria is more likely to come back.
If you feel that your child is not getting better within two days, or are getting worse, you
must come back to the clinic or hospital at once.
We do not want to include in this study: pregnant women, children who are less than 5
years, or people who are more than 70 years.
Please Return on………………………………………………………(Date)
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Patient information sheet - children - Zulu translation
Iphepha lesaziso seziguli ngokuhlolwa kwezinsuku eziwu-28 emva
kokuthatha amaphilisi i-coartemTM eyelapha umalaleveva
Mnumzane/Nkosikazi
Igama lami ngingu Dr CHV Williams, ngisebenza e-Mkhanyakude emnyangweni
wezempilo. Imininingwane yekheli ikanje:
Umkhanyakude Health District Office
Jozini 3969
Izinombolo zocingo: 035 572 1357; 072 584 3472
I-Email: hervey.williams@kznhealth.gov.za
Ukuhlolwa kwegazi lengane yakho kukhombise ukuthi inomalaleveva okungaba isifo
esinobungozi kakhulu.
Kusukela ngonyaka ka-2001 i-CoaratemTM yasetshenziswa ukwelapha umaleveva
KwaZulu-Natal.  Ibonakale isebenza kahle kakhulu, kodwa sisafuna ukuhlola ukhuthi
isaqhubeka nokusebenza kahle ekwelapheni kwalesisifo.
Ebesikucela kuwena ukuba usinikeze imvumo yokuthi sithathe elinye futhi iconsi legazi
lengane yakho namuhla ukuze sizokwazi ukuqhuba lolucwaningo lukamalaleveva
egazini lakho. Uyacelwa futhi ukuba uphinde ubuye emva kwamasonto amane
ukuzoqhubeka nokuhlolelwa lesisifo, lapho-ke sizophinde sikucele futhi ukuba
usinikeze enye imvumo yokuthatha elinye iconsi legazi lengane ukuze siqinisekise
ukuthi welapheke ngempela kumalaleveva.
Igazi lengane yakho lizosetshenziswa ukhuhlolelwa umalaleveva nje kuphela, hhayi
okunye. Kulokhukuhlolwa amaphilisi owatholayo azoqhubeka afane nabobonke abanye
abaphethwe umalaleveva umehluko ukuthi nje sizobe simbheke umntwana eduze
kunabanye ngokulokhu sikucela ukuba ubuye njalo emtholampilo uma kudingekile.
Lolu cwaningo luvnyelwe labhekwa ngokwesisekelo sezinkolelo yiUKZN Biomedical
research ethics committee ( inombolo esemtethweni………)
Uma uneminye imibuzo/izinkinga ungangaxhumana noDr CHV Williams kulekheli
elilandelayo:
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION
Research office , Westville campus Govan Mbeki Building
Private Bag X54001, Durban 4000
KwaZulu-Natal, South Africa
Tel: 27 31 2604769-Fax:27 31 2604609; Email: BREC@ukzn.ac.za
Sifisa ukukwazisa ukuthi awuphoqwanga ukuba yingxenye yalolucwaningo
lokuhlolelwa umalaleveva nokuthi ulokhu ubuya njalo emva kwamasonto amane
ukuzohlolwa emtholampilo . Uma ungathandi ukuba yingxenye yalolucwaningo
uvumelekile ukwenqaba. Noma wenqabile uzoqhubeka ukunikwa amaphilisi okwelapha
umalaleveva njengokwejwayelekile.
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Uma kumele ubuye emva kwamasonto amane uzonikezwa imali yokugibela engango
R50.
Imiphumela yalolu cwaningo izoshicilelwa, kodwa ayikho imininigwane yomuntu
ezovezwa. Imininigwane yakho etholakale kulolucwaningo iyimfihlo, angeke ivezelwe
abantu abangangekho emphathini walolucwaningo.
I consi legazi eliqandisiwe lanomawubani lizo bekwa eMalaria Research Programme
laboratory ye Medical research council eThekwini lapho izosetshenziselwa eminye
imicwaningo esikhathini esiphambilini.
 Ingane yakho kumele ithathe amaphilisi awu___ eCoartemTM, kabili ngosuku izinsuku
ezintathu. Lamaphilisi kumele iwathathe nobisi noma emvakokudla aze aphele. Uma
ingawathathanga njengoba uyaliwe maningi amathuba okuthi iphinde iphathwe
umalaleveva.
Uma uzizwa ungabingcono, noma ukugula kuqhubekela phambili emva kwezinsuku
ezimbili, kumele ubuye masinyane emtholampilo noma esibhedlela.
Abakhulelwe, izingane ezingaphansi kweminyaka emihlanu (5) nabadala abangaphezu
kweminyaka engamashumi ayisikhombisa (70) abavumelekile ukuba yingxenye
yalolucwaningo.
Uyacelwa ukuba ubuye ngomhlaka……………………………………………………
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Consent Form (English-Adults)
Consent form for 28 day follow-up after treatment with coartem™ to treat
P. falciparum malaria
I agree to return on……………………………..for a blood test see if the malaria has
gone away.
I,………………………………………………………….., have been informed about the
study entitled:
‘Assessment of the therapeutic efficacy of artemether-lumefantrine in the
treatment of uncomplicated plasmodium falciparum malaria in northern
KwaZulu-Natal’
by (…………………………………………………………….).
 I understand the purpose and procedures of the study.
 I have been given an opportunity to answer questions about the study and have
had answers to my satisfaction.
 I declare that my participation in this study is entirely voluntary and that I may
withdraw at any time without affecting any treatment or care that I would usually
be entitled to.
If I have any further questions/concerns or queries related to the study I understand
that I may contact the researcher,
Dr CHV Williams,
Umkhanyakude Health District Office, Jozini, 3969
Telephone: 035 5721357; Cellphone: 072 584 3472,
Email: hervey.williams@kznhealth.gov.za
If I have any questions or concerns about my rights as a study participant, or if I am
concerned about an aspect of the study or the researchers then I may contact:
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION
Research Office, Westville CampusGovan Mbeki Building
Private Bag X 54001, Durban 4000
KwaZulu-Natal, SOUTH AFRICA
Tel: 27 31 2604769 - Fax: 27 31 2604609; Email: BREC@ukzn.ac.za
____________________ ____________________
Signature of Participant                            Date
____________________ _____________________
Signature of Witness                                Date
(Where applicable)
____________________ _____________________
Signature of Translator                            Date
(Where applicable)
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Consent form adults – Zulu translation
Imvume yokuhlolwa emva kwezinsuku eziwu-28 uthathe amaphilisi i-
coartem™ eyelapha umalaleveva
Mina (igama nesibongo) __________________________Ngiyavuma ukubuya
ngomhlaka (usuku)_____________ngizohlolwa igazi, ukuze kubhekwe ukuthi
welapheke ngempela umalaleveva.
Ungazisile u –(igama lomuntu okwazise ngalolucwaningo)
_________________________ ngalolucwaningo lukamalaleveva lokubheka
ukusebenza kwamaphilisi i-coartem asentshenziswa ekwelapheni lesisifo lapha
KwaZulu Natal
 Ngiyasizwa isizathu nendlela ezosentshenziswa kulolucwaningo.
 Nginikiwe ithuba lokubuza imibuzo  ngalolucwaningo futhi izimpendulo
engizinikeziwe zingenelisile.
 Ngiyaqinisekisa ukuthi angiphoqwanga ukuba yingxenye yalolucwaningo
nokuthi ngazisiwe ukuthi ngingaphuma noma yinini uma ngingasathandi ukuba
yingxenye ngaphandle kokuphazamiseka kokwelashelwa kwami lesisifo.
 Ngiyazi futhi ukuthi uma ngineminye imibuzo/izinkinga namganoma yini
engingayiqondi kahle mayelana nalolucwaningo ngingaxhumana nomhloli
omkhulu walolucwaningo okungu -Dr CHV Williams, kulelikheli elilandelayo:
Umkhanyakude Health District office, Jozini, 3969
Izinombolo zocingo: 0355721357; 0725843472, I-Email:
hervey.williams@kznhealth.gov.za
Ngiyazi futhi ukuthi uma ngineminye imibuzo ngamalungelo ami okuba yingxenye
yalolucwaningo, nanoma ngabe yini engingayiqondi kahle ngalolucwaningo
nangomcwaningi ngingaxhumana namahhovisi ezocwaningo kulelikheli elilandelayo:
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION,
Research Office, Westville Campus Govan Mbeki Building
Private Bag X54001, Durban 4000
KwaZulu-Natal, SOUTH AFRICA
Inombolo yocingo: 27312604769- Fax: 27312604609; Email: BREC@ukzn.ac.za
_____________________                                        ________________________
Isiginesha yami usuku
______________________________ ___________________________
Isiginesha kafakazi (lapho edingekile) usuku
_______________ ____________________________
Isiginesha yomhumushi (lapho edingekile) usuku
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Consent Form (English-Children)
Consent form for 28 day follow-up after treatment with coartem™ to treat
P. falciparum malaria
I ………………………agree to return with my child………………….
on……………………………..for a blood test see if the malaria has gone away.
I,………………………………………………………….. have been informed about the
study entitled:
‘Assessment of the therapeutic efficacy of artemether-lumefantrine in the
treatment of uncomplicated plasmodium falciparum malaria in northern
KwaZulu-Natal’
by (…………………………………………………………….).
 I understand the purpose and procedures of the study.
 I have been given an opportunity to answer questions about the study and have
had answers to my satisfaction.
 I declare that the participation of my child in this study is entirely voluntary and
that I may withdraw my child at any time without affecting any treatment or care
that my child would usually be entitled to.
If I have any further questions/concerns or queries related to the study I understand
that I may contact the researcher,
Dr CHV Williams,
Umkhanyakude Health District Office, Jozini, 3969
Telephone: 035 5721357; Cell phone: 072 584 3472,
Email: hervey.williams@kznhealth.gov.za
If I have any questions or concerns about the rights of my child as a study participant,
or if I am concerned about an aspect of the study or the researchers then I may
contact:
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION
Research Office, Westville Campus Govan Mbeki Building
Private Bag X 54001, Durban 4000
KwaZulu-Natal, SOUTH AFRICA
Tel: 27 31 2604769 - Fax: 27 31 2604609; Email: BREC@ukzn.ac.za
___________________________ ____________________
Signature of Parent or Guardian Date
____________________ _____________________
Signature of Witness Date
(Where applicable)
____________________ _____________________
Signature of Translator Date
(Where applicable)
82
Consent form children – Zulu translation
Imvume yokuhlolwa emva kwezinsuku eziwu-28 uthathe amaphilisi i-
coartem™ eyelapha umalaleveva
Mina ______________________(igama nesibongo) ngiyavuma ukuletha ingane yami
ongu (igama nesibongo somntwana)____________________ ngomhlaka
(usuku)_______________ ukuze ahlolwe igazi kubhekwe ukuthi welapheke ngempela
kumalaleveva.
Mina ngazisiwe u–(igama lomuntu okwazise ngalolucwaningo)
_________________________ ngalolucwaningo lukamalaleveva lokubheka
ukusebenza kwamaphilisi i-coartem asentshenziswa ekwelapheni lesisifo lapha
KwaZulu Natal
 Ngiyasizwa isizathu nendlela ezosentshenziswa kulolucwaningo.
 Nginikiwe ithuba lokubuza imibuzo  ngalolucwaningo futhi izimpendulo
engizinikeziwe zingenelisile.
 Ngiyaqinisekisa ukuthi angiphoqwanga ukuba yingxenye yalolucwaningo
nokuthi ngazisiwe ukuthi ngingaphuma noma yinini uma ngingasathandi ukuba
yingxenye ngaphandle kokuphazamiseka kokwelashelwa kwami lesisifo.
 Ngiyazi futhi ukuthi uma ngineminye imibuzo/izinkinga namganoma yini
engingayiqondi kahle mayelana nalolucwaningo ngingaxhumana nomhloli
omkhulu walolucwaningo okungu -Dr CHV Williams, kulelikheli elilandelayo:
Umkhanyakude Health District office, Jozini, 3969
Izinombolo zocingo: 0355721357; 0725843472, I-Email:
hervey.williams@kznhealth.gov.za
Ngiyazi futhi ukuthi uma ngineminye imibuzo ngamalungelo ami okuba yingxenye
yalolucwaningo, nanoma ngabe yini engingayiqondi kahle ngalolucwaningo
nangomcwaningi ngingaxhumana namahhovisi ezocwaningo kulelikheli elilandelayo:
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION,
Research Office, Westville Campus Govan Mbeki Building
Private Bag X54001, Durban 4000
KwaZulu-Natal, SOUTH AFRICA
Inombolo yocingo: 27312604769- Fax: 27312604609; Email: BREC@ukzn.ac.za
_____________________                                        ________________________
Isiginesha yami usuku
______________________________ ___________________________
Isiginesha kafakazi (lapho edingekile) usuku
_______________ ____________________________
Isiginesha yomhumushi (lapho edingekile) usuku
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Letter of permission from District Office
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Malaria Journal is aimed at the scientific community interested in malaria in its broadest sense. It is the only journal that
publishes exclusively articles on malaria and, as such, it aims to bring together knowledge from the different specialties
involved in this very broad discipline, from the bench to the bedside and to the field. Malaria Journal offers a fast
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Submission process
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their
behalf. The submitting author takes responsibility for the article during submission and peer review.
Please note that Malaria Journal levies an article-processing charge on all accepted Research Articles; if the submitting
author's institution is a BioMed Central member the cost of the article-processing charge may be covered by the
membership (see About page for detail). Please note that the membership is only automatically recognised on submission
if the submitting author is based at the member institution.
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To facilitate rapid publication and to minimize administrative costs, Malaria Journal accepts only online submission.
Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time; when users
return to the site, they can carry on where they left off.
See below for examples of word processor and graphics file formats that can be accepted for the main manuscript
document by the online submission system. Additional files of any type, such as movies, animations, or original data
files, can also be submitted as part of the manuscript.
During submission you will be asked to provide a cover letter. Use this to explain why your manuscript should be
published in the journal, to elaborate on any issues relating to our editorial policies in the 'About Malaria Journal' page,
and to declare any potential competing interests. You will be also asked to provide the contact details (including email
addresses) of potential peer reviewers for your manuscript. These should be experts in their field, who will be able to
provide an objective assessment of the manuscript. Any suggested peer reviewers should not have published with any of
the authors of the manuscript within the past five years, should not be current collaborators, and should not be members
of the same research institution. Suggested reviewers will be considered alongside potential reviewers recommended by
Editorial Board members or other advisers.
Assistance with the process of manuscript preparation and submission is available from BioMed Central customer
support team.
We also provide a collection of links to useful tools and resources for scientific authors on our Useful Tools page.
File formats
The following word processor file formats are acceptable for the main manuscript document:
Microsoft word (DOC, DOCX)
Rich text format (RTF)
Portable document format (PDF)
TeX/LaTeX (use BioMed Central's TeX template)
DeVice Independent format (DVI)
Users of other word processing packages should save or convert their files to RTF before uploading. Many free tools are
available which ease this process.
TeX/LaTeX users: We recommend using BioMed Central's TeX template and BibTeX stylefile. If you use this standard
format, you can submit your manuscript in TeX format. If you have used another template for your manuscript, or if you
do not wish to use BibTeX, then please submit your manuscript as a DVI file. We do not recommend converting to RTF.
Note that figures must be submitted as separate image files, not as part of the submitted manuscript file.
Preparing main manuscript text
General guidelines of the journal's style and language are given below.
Overview of manuscript sections for Research Articles
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Illustrations and figures (if any)
Tables and captions
Preparing additional files
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript
should be provided, in square brackets and include the corresponding database name; for example, [EMBL:AB026295,
EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data
Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource
(PIR) and the Swiss-Prot Protein Database (Swiss-Prot).
You can download a template (Mac and Windows compatible; Microsoft Word 98/2000) for your article.
For reporting standards please see the information in the About section.
Title page
The title page should:
provide the title of the article
list the full names, institutional addresses and email addresses for all authors
indicate the corresponding author
Please note:
the title should include the study design, for example "A versus B in the treatment of C: a randomized controlled trial X is a risk factor for Y: a case control
study"
abbreviations within the title should be avoided
Abstract
The Abstract of the manuscript should not exceed 350 words and must be structured into separate sections: Background,
the context and purpose of the study; Methods, how the study was performed and statistical tests used; Results, the main
findings; Conclusions, brief summary and potential implications. Please minimize the use of abbreviations and do not
cite references in the abstract. Trial registration, if your research reports the results of a controlled health care
intervention, please list your trial registry, along with the unique identifying number (e.g. Trial registration: Current
Controlled Trials ISRCTN73824458). Please note that there should be no space between the letters and numbers of your
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trial registration number. We recommend manuscripts that report randomized controlled trials follow the CONSORT
extension for abstracts.
Keywords
Three to ten keywords representing the main content of the article.
Background
The Background section should be written in a way that is accessible to researchers without specialist knowledge in that
area and must clearly state - and, if helpful, illustrate - the background to the research and its aims. Reports of clinical
research should, where appropriate, include a summary of a search of the literature to indicate why this study was
necessary and what it aimed to contribute to the field. The section should end with a brief statement of what is being
reported in the article.
Methods
The methods section should include the design of the study, the setting, the type of participants or materials involved, a
clear description of all interventions and comparisons, and the type of analysis used, including a power calculation if
appropriate. Generic drug names should generally be used. When proprietary brands are used in research, include the
brand names in parentheses in the Methods section.
For studies involving human participants a statement detailing ethical approval and consent should be included in the
methods section. For further details of the journal's editorial policies and ethical guidelines see 'About this journal'.
For further details of the journal's data-release policy, see the policy section in 'About this journal'.
Results and discussion
The Results and discussion may be combined into a single section or presented separately. Results of statistical analysis
should include, where appropriate, relative and absolute risks or risk reductions, and confidence intervals. The Results
and discussion sections may also be broken into subsections with short, informative headings.
Conclusions
This should state clearly the main conclusions of the research and give a clear explanation of their importance and
relevance. Summary illustrations may be included.
List of abbreviations
If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be
provided, which should precede the competing interests and authors' contributions.
Competing interests
A competing interest exists when your interpretation of data or presentation of information may be influenced by your
personal or financial relationship with other people or organizations. Authors must disclose any financial competing
interests; they should also reveal any non-financial competing interests that may cause them embarrassment were they to
become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be
listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s)
declare that they have no competing interests'.
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Financial competing interests
In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any
way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization
financing this manuscript (including the article-processing charge)? If so, please specify.
Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of
this manuscript, either now or in the future? If so, please specify.
Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received
reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content
of the manuscript? If so, please specify.
Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual,
commercial or any other) to declare in relation to this manuscript? If so, please specify.
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial
office.
Authors' contributions
In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript
should be specified in this section.
An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published
study. To qualify as an author one should 1) have made substantial contributions to conception and design, or acquisition
of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for
important intellectual content; and 3) have given final approval of the version to be published. Each author should have
participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of
funding, collection of data, or general supervision of the research group, alone, does not justify authorship.
We suggest the following kind of format (please use initials to refer to each author's contribution): AB carried out the
molecular genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the
immunoassays. MT participated in the sequence alignment. ES participated in the design of the study and performed the
statistical analysis. FG conceived of the study, and participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
All contributors who do not meet the criteria for authorship should be listed in an acknowledgements section. Examples
of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a
department chair who provided only general support.
Authors' information
You may choose to use this section to include any relevant information about the author(s) that may aid the reader's
interpretation of the article, and understand the standpoint of the author(s). This may include details about the authors'
qualifications, current positions they hold at institutions or societies, or any other relevant background information.
Please refer to authors using their initials. Note this section should not be used to describe any competing interests.
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Butterworth-Heinemann; 1996.
Complete book
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970.
Monograph or book in a series
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and Tissues. Edited by Harris TJR.
New York: Academic Press; 1995:54-56. [Stoner G (Series Editor): Methods and Perspectives in Cell Biology, vol 1.]
Book with institutional author
Advisory Committee on Genetic Modification: Annual Report. London; 1999.
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PhD thesis
Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD thesis. Stanford University,
Computer Science Department; 1995.
Link / URL
The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do]
Link / URL with author(s)
Neylon C: Open Research Computation: an ordinary journal with extraordinary aims.
[http://blogs.openaccesscentral.com/blogs/bmcblog/entry/open_research_computation_an_ordinary]
Dataset with persistent identifier
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; Liu, C-M; Jing, H-C
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Preparing illustrations and figures
Illustrations should be provided as separate files, not embedded in the text file. Each figure should include a single
illustration and should fit on a single page in portrait format. If a figure consists of separate parts, it is important that a
single composite illustration file be submitted which contains all parts of the figure. There is no charge for the use of
color figures.
Please read our figure preparation guidelines for detailed instructions on maximising the quality of your figures.
Formats
The following file formats can be accepted:
PDF (preferred format for diagrams)
DOCX/DOC (single page only)
PPTX/PPT (single slide only)
EPS





The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the
figure file. For each figure, the following information should be provided: Figure number (in sequence, using Arabic
numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words.
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to
reproduce figures or tables that have previously been published elsewhere.
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Preparing a personal cover page
If you wish to do so, you may submit an image which, in the event of publication, will be used to create a cover page for
the PDF version of your article. The cover page will also display the journal logo, article title and citation details. The
image may either be a figure from your manuscript or another relevant image. You must have permission from the
copyright to reproduce the image. Images that do not meet our requirements will not be used.
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image).
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and screen dumps), JPEG, BMP, DOC,
PPT, CDX, TGF (ISIS/Draw).
Preparing tables
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also
have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends
may then follow, but they should be concise. Tables should always be cited in text in consecutive numerical order.
Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4
portrait or landscape format. These will be typeset and displayed in the final published form of the article. Such tables
should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept aligned
when the file is sent electronically for review; this will not always be the case if columns are generated by simply using
tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell
display as black lines. Commas should not be used to indicate numerical values. Color and shading may not be used;
parts of the table can be highlighted using symbols or bold text, the meaning of which should be explained in a table
legend. Tables should not be embedded as figures or spreadsheet files.
Larger datasets or tables too wide for a landscape page can be uploaded separately as additional files. Additional files
will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the
author.
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls) or comma separated values
(.csv). As with all files, please use the standard file extensions.
Preparing additional files
Although Malaria Journal does not restrict the length and quantity of data included in an article, we encourage authors to
provide datasets, tables, movies, or other information as additional files.
Please note: All Additional files will be published along with the article. Do not include files such as patient consent
forms, certificates of language editing, or revised versions of the main manuscript document with tracked changes. Such
files should be sent by email to malariajournal@biomedcentral.com, quoting the Manuscript ID number.
Results that would otherwise be indicated as "data not shown" can and should be included as additional files. Since many
weblinks and URLs rapidly become broken, Malaria Journal requires that supporting data are included as additional
files, or deposited in a recognized repository. Please do not link to data on a personal/departmental website. The
maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission.
Additional files can be in any format, and will be downloadable from the final published article as supplied by the author.
We encourage authors to use formats which facilitate reuse. e.g. We recommend CSV rather than PDF for tabular data.
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Certain supported files formats are recognized and can be displayed to the user in the browser. These include most movie
formats (for users with the Quicktime plugin), mini-websites prepared according to our guidelines, chemical structure
files (MOL, PDB), geographic data files (KML).
If additional material is provided, please list the following information in a separate section of the manuscript text:
File name (e.g. Additional file 1)
File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and a URL of an
appropriate viewer if format is unusual)
Title of data
Description of data
Additional files should be named "Additional file 1" and so on and should be referenced explicitly by file name within
the body of the article, e.g. 'An additional movie file shows this in more detail [see Additional file 1]'.
Additional file formats
Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely









XLS, XLSX (Excel Spreadsheet)
CSV (Comma separated values)
As with figure files, files should be given the standard file extensions.
Mini-websites
Small self-contained websites can be submitted as additional files, in such a way that they will be browsable from within
the full text HTML version of the article. In order to do this, please follow these instructions:
Create a folder containing a starting file called index.html (or index.htm) in the root.
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Put all files necessary for viewing the mini-website within the folder, or sub-folders.
Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or
"http://yourdomain.net/images/picture.jpg" or "C:\Documents and Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 characters.
Access the index.html file and browse around the mini-website, to ensure that the most commonly used browsers
(Internet Explorer and Firefox) are able to view all parts of the mini-website without problems, it is ideal to check
this on a different machine.
Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the root of the ZIP,
and that the file has .zip extension, then submit as an additional file with your article.
Style and language
General
Currently, Malaria Journal can only accept manuscripts written in English. Spelling should be US English or British
English, but not a mixture.
There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise. There is also no
restriction on the number of figures, tables or additional files that can be included with each article online. Figures and
tables should be numbered in the order in which they are referred to in the text. Authors should include all relevant
supporting data with each article.
Malaria Journal will not edit submitted manuscripts for style or language; reviewers may advise rejection of a
manuscript if it is compromised by grammatical errors. Authors are advised to write clearly and simply, and to have their
article checked by colleagues before submission. In-house copyediting will be minimal. Non-native speakers of English
may choose to make use of a copyediting service.
Help and advice on scientific writing
The abstract is one of the most important parts of a manuscript. For guidance, please visit our page on Writing titles and
abstracts for scientific articles.
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. American Scientist also
provides a list of resources for science writing. For more detailed guidance on preparing a manuscript and writing in
English, please visit the BioMed Central author academy.
Abbreviations
Abbreviations should be used as sparingly as possible. They should be defined when first used and a list of abbreviations
can be provided following the main manuscript text.
Typography
Please use double line spacing.
Type the text unjustified, without hyphenating words at line breaks.
Use hard returns only to end headings and paragraphs, not to rearrange lines.
Capitalize only the first word, and proper nouns, in the title.
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All pages should be numbered.
Use the Malaria Journal reference format.
Footnotes are not allowed, but endnotes are permitted.
Please do not format the text in multiple columns.
Greek and other special characters may be included. If you are unable to reproduce a particular special character, please
type out the name of the symbol in full. Please ensure that all special characters used are embedded in the text,
otherwise they will be lost during conversion to PDF.
Units
SI units should be used throughout (liter and molar are permitted, however).
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UKZN Biomedical Research Ethics Committee Approval
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BREC is registered with the South African National Health Research Ethics Council (REC. 
290408-009). BREC has US Office for Human Research Protections (OHRP) Federal-widE 
Assurance (FWA 678). 
Yours sincerely 
rs A Marimuthu 
· Senior Administrator: Biomedical Research Ethics 
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KwaZulu-Natal Health Research Committee Approval
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UKZN Postgraduate Education Committee Approval
-----Original Message-----
From: Anna Voce [mailto:voceas@ukzn.ac.za]
Sent: 23 November 2011 04:19 PM
To: 983215818 Charles Hervey Vaughan-Williams
Cc: Stephen Knight; Mbokazi@ukzn.ac.za; oreilly@ukzn.ac.za
Subject: [NRMSM] Provisional Approval
Dear Dr Knight
RE:  Assessment of the therapeutic efficacy of artemether-lumefantrine in the
treatment of uncomplicated Plasmodium falciparum malaria in northern KwaZulu-
Natal.  CH Vaughan-Williams.
The Postgraduate Education Committee considered the abovementioned
application and raised various queries.  These have been addressed and the
protocol is given provisional approval for the Master of Public Health degree.
This decision will be ratified at a full sitting of the Committee scheduled for 6th
December 2011.
Please note that the study may not begin without ethics approval.
Yours sincerely
Dr A Voce



































2012/01/11 1 40 f Yes Yes Yes Yes 65 2012/01/11 Moz Neg Thukuze Moz 36.5
2012/01/12 2 21 f Yes No No No
2012/01/12 3 Yes No No No
2012/01/16 4 7 m Yes Yes No No 19 2012/01/15 Paracetamol Yes
Non-
reactive Lulwane South Africa 39.4
2012/01/19 5 32 f Yes No No No 58 2012/01/28 Arvs None Pos Thengani South Africa 36.4
2012/01/23 6 24 m Yes Yes Yes Yes 57 2012/01/21 Nil None NK Moz Moz 39.3
2012/01/31 8 9 f Yes No Yes Yes 25
2012/01/31 7 Yes No No No
2012/02/10 9 30 f Yes Yes Yes No 61 2012/02/18 Paracetamol None NK Skhemelele South Africa 36.5
2012/02/26 10 31 m Yes Yes Yes No 56 2012/02/23 Nil Moz NK Manhlali South Africa 38.3
2012/02/27 11 6 m Yes No Yes Yes 20.9
2012/02/29 12 8 f Yes Yes Yes Yes 20.6 2012/02/23 antibiotics None NK
KwaMakhany
a South Africa 36.7
2012/03/01 13 28 f Yes Yes No No 51.5 2012/02/25 Nil Moz NK Mozambique Mozambique 37.1
2012/03/09 14 28 f Yes Yes No No 71.7 2012/03/08 Paracetamol None
Non-
reactive Embangweni South Africa 36
2012/03/09 15 69 f Yes Yes No No 61 2012/03/08 Nil Moz NK Makhabeleni South Africa 38.7
2012/03/12 17 5 f Yes Yes No No 23.8 2012/03/06 Paracetamol None
Non-
reactive Embangweni South Africa 40
2012/03/12 16 6 f Yes Yes No No 20.7 2012/03/06 Paracetamol None
Non-
reactive Embangweni South Africa 38.1
2012/03/12 22 43 m Yes Yes No No 66 2012/03/10 Nil Moz nk Mbangweni South Africa 38.4
2012/03/13 19 15 m Yes Yes No No 42 2012/03/09 Paracetamol Moz NK Embangweni South Africa 38
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2012/03/13 18 45 f Yes Yes No No 2012/03/10 Paracetamol None
Non-
reactive Embangweni South Africa
2012/03/19 21 34 m Yes Yes No No 34 South Africa 35.8
2012/03/19 23 48 m Yes Yes 65 2012/03/01 Paracetamol None NK Mbangweni South Africa 37.1
2012/03/26 24 12 m Yes Yes no no 34 2012/03/14 Paracetamol None NK Mbangweni South Africa 37
2012/04/02 25 37 f Yes Yes No No 106 2012/03/29 Pos KwaNdaba South Africa 38.7
2012/04/13 26 29 f Yes Yes No No 72 2012/02/12 Paracetamol None Yes' Ward 9 South Africa 36.8
2012/04/17 27 6 f Yes Yes Yes Yes 20 2012/04/14 Paracetamol None Yes' Mbangweni South Africa 39
2012/04/18 29 2 m Yes Yes No No 20 2012/04/16 Paracetamol None Nk Bhekabantu South Africa 39
2012/04/20 30 2 f Yes Yes No No 2012/04/18 Paracetamol Moz NK Embangweni South Africa
2012/04/20 32 7 m Yes Yes No No 24 2012/04/18 Paracetamol None NK Bhekabantu South Africa 39.7
2012/04/20 31 17 m Yes Yes No No 59 2012/04/15 Paracetamol None NK Embangweni South Africa 38.2
2012/04/24 34 14 f Yes Yes No No 52 2012/04/22 Paracetamol None NK Bhekabantu South Africa 38
2012/04/26 48 66 f Yes Yes No No 49 2012/04/26 Paracetamol Moz Nk Bhekabantu South Africa 37.5
2012/04/30 35 4 f Yes Yes No No 15.2 2012/04/26 Paracetamol Moz Yes' Mbangweni South Africa 38
2012/04/30 33 23 f Yes Yes No No 50 2012/04/25 Paracetamol None Yes' Bhekabantu South Africa 36.5
2012/05/02 38 3 m Yes
FU form
used No No 15 38
2012/05/02 28 5 f Yes Yes No No 18 2012/05/01 Paracetamol None NK Bhekabantu South Africa 38.6
2012/05/02 37 5 f Yes
FU form
used No No 17 2012/05/02 38
2012/05/02 36 8 f Yes Yes No No 17 2012/05/01 Paracetamol None NK Bhekabantu South Africa 39
2012/05/02 44 13 m Yes Yes No No 40 2012/05/01 Paracetamol None NK Bhekabantu South Africa 37
2012/05/04 40 6 f Yes Yes no No 17 2012/05/02 Paracetamol None NK Bhekabantu South Africa 37.7
2012/05/04 43 13 m Yes
FU form
used No No 47 38
2012/05/04 39 14 m Yes Yes No No 32 2012/05/03 Paracetamol None NK Bhekabantu South Africa 38.1
2012/05/04 42 15 m Yes Yes No No 51 2012/05/03 Paracetamol None Nk Bhekabantu South Africa 37.7
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2012/05/04 41 38 f Yes
FU form
used No No 57 37.2
2012/05/06 45 39 m Yes Yes No No 79 2012/05/05 Paracetamol None NK Bhekabantu South Africa 37
2012/05/07 46 12 f Yes Yes no No 32 2012/05/04 Paracetamol None NK KwaNdaba South Africa 37.5
2012/05/07 47 12 f Yes Yes No No 46 2012/05/04 Paracetamol None NK Bhekabantu South Africa 37.8























82 113/72 Pos Pos Pos P. falciparum 4 2012/02/08 2012/02/08 28 37 82 110/70
Pos Neg Neg Negative 2012/02/09
Pos No record Neg Negative 2012/02/09
Pos No record Pos P. falciparum 2 2012/02/13 2012/07/25 191
80 122/93 Pos Neg Pos P. falciparum 2012/02/16 2012/07/05 168
110 126/57 Pos Neg Pos P. falciparum 4 2012/02/20 2012/03/12 49 36.7 60 120/89 Yes
Pos Neg Neg Pos P. falciparum 2012/02/28 2012/02/29 29 36 102 Yes
Pos Neg Negative 2012/02/28
93 104/73 Pos Neg Negative 4 2012/03/09 2012/03/30 49
92 95/56 Pos Pos P. falciparum 4 2012/03/25 2012/03/29 32
Pos Neg Negative 2 2012/03/26 2012/03/23 25 37 96 yes
100 Pos Pos P. falciparum 2 2012/03/28 2012/03/29 29 36 118 yes
84 93/61 Pos Neg Negative 2 2012/03/29
78 130/80 Pos Neg Negative 4 2012/04/06
90 155/93 Pos Neg Negative 4 2012/04/06
118 Pos Neg Negative 2 2012/04/09
120 Pos Neg Negative 2 2012/04/09
78 100/70 Pos neg Negative 4 2012/04/09
110 Pos Pos P. falciparum 4 2012/04/10 2012/06/27 106
100 120/70 Pos Pos P. falciparum 4 2012/04/10 2012/07/18 127
Pos neg Negative 4 2012/04/10
78 140/80 Pos neg Negative 4 2012/04/16
96 120/60 Pos neg Negative 4 2012/04/16
96 Pos neg Negative 3 2012/04/23
86 110/77 Pos Pos P. falciparum 4 2012/04/30 2012/06/27 86
106
Pos No record Neg Negative 2012/02/09
Pos No record Pos P. falciparum 2 2012/02/13 2012/07/25 191
80 122/93 Pos Neg Pos P. falciparum 2012/02/16 2012/07/05 168
110 126/57 Pos Neg Pos P. falciparum 4 2012/02/20 2012/03/12 49 36.7 60 120/89 Yes
Pos Neg Neg Pos P. falciparum 2012/02/28 2012/02/29 29 36 102 Yes
Pos Neg Negative 2012/02/28
93 104/73 Pos Neg Negative 4 2012/03/09 2012/03/30 49
92 95/56 Pos Pos P. falciparum 4 2012/03/25 2012/03/29 32
Pos Neg Negative 2 2012/03/26 2012/03/23 25 37 96 yes
100 Pos Pos P. falciparum 2 2012/03/28 2012/03/29 29 36 118 yes
84 93/61 Pos Neg Negative 2 2012/03/29
78 130/80 Pos Neg Negative 4 2012/04/06
90 155/93 Pos Neg Negative 4 2012/04/06
118 Pos Neg Negative 2 2012/04/09
120 Pos Neg Negative 2 2012/04/09
78 100/70 Pos neg Negative 4 2012/04/09
110 Pos Pos P. falciparum 4 2012/04/10 2012/06/27 106
100 120/70 Pos Pos P. falciparum 4 2012/04/10 2012/07/18 127
Pos neg Negative 4 2012/04/10
78 140/80 Pos neg Negative 4 2012/04/16
96 120/60 Pos neg Negative 4 2012/04/16
96 Pos neg Negative 3 2012/04/23
86 110/77 Pos Pos P. falciparum 4 2012/04/30 2012/06/27 86
90 133/87 Pos neg Negative 4 2012/05/11
112 Pos Pos P. falciparum 2 2012/05/15 2012/05/15 28 36 116 yes
107
156 Pos Negative 1 2012/05/16
Pos P. falciparum ? 2012/05/18
Gone to Moz;
unobtainable
102 Pos NS Neg Negative 2 2012/05/18
106 105/62 Pos Pos P. falciparum 4 2012/05/18 2012/06/28 69
Pos Pos P. falciparum 4 2012/05/22 2012/07/25 92
96 136/87 Pos Neg Negative 4 2012/05/24
120 Pos Pos P. falciparum 1 2012/05/28 2012/06/28 59
94 117/66 Pos Neg Negative 4 2012/05/28
100 Pos Pos P. falciparum 2 2012/05/30 2012/06/28 57
110 Pos NS Negative 2 2012/05/30
104 Pos Neg Negative 2 2012/05/30
120 Pos NS Neg Negative 2 2012/05/30
100 110/70 Pos Neg Negative 2 2012/05/30
120 Pos NS Neg Negative 2 2012/06/01
102 100/60 Pos NS Neg Negative 4 2012/06/01
100 100/70 Pos NS Neg Negative 3 2012/06/01
100 110/70 Pos NS Neg Negative 4 2012/06/01
100 130/80 Pos NS Neg Negative 2 2012/06/01
88 110/70 Pos NS Neg Negative 4 2012/06/03
100 100/60 Pos NS Neg Negative 3 2012/06/04
102 100/70 Pos NS Neg Negative 4 2012/06/04
92 120/70 Pos Neg Negative 4 2012/06/12
